U.S. patent number 10,267,797 [Application Number 15/939,382] was granted by the patent office on 2019-04-23 for detection of oral microbial virulence factors.
This patent grant is currently assigned to The Procter & Gamble Company. The grantee listed for this patent is The Procter & Gamble Company. Invention is credited to Benjamin Thomas Circello, John Christian Haught, Thomas Glenn Huggins, Deepa Ashok Khambe, Malgorzata Klukowska, Cheryl Sue Tansky, Donald James White, Sancai Xie.
![](/patent/grant/10267797/US10267797-20190423-D00001.png)
![](/patent/grant/10267797/US10267797-20190423-D00002.png)
![](/patent/grant/10267797/US10267797-20190423-D00003.png)
![](/patent/grant/10267797/US10267797-20190423-D00004.png)
![](/patent/grant/10267797/US10267797-20190423-D00005.png)
![](/patent/grant/10267797/US10267797-20190423-D00006.png)
![](/patent/grant/10267797/US10267797-20190423-D00007.png)
![](/patent/grant/10267797/US10267797-20190423-D00008.png)
![](/patent/grant/10267797/US10267797-20190423-D00009.png)
![](/patent/grant/10267797/US10267797-20190423-D00010.png)
![](/patent/grant/10267797/US10267797-20190423-D00011.png)
View All Diagrams
United States Patent |
10,267,797 |
Haught , et al. |
April 23, 2019 |
Detection of oral microbial virulence factors
Abstract
Methods for detecting and quantifying toxins present in the oral
cavity. The methods may include providing a biological sample,
providing reporter cells expressing one or more Toll like
receptors, exposing the cells to the biological sample, measuring
the EC50 value of the lipopolysaccharide on activation of a Toll
like receptor, quantification of the lipopolysaccharide in the
biological sample.
Inventors: |
Haught; John Christian (West
Chester, OH), Xie; Sancai (Liberty Township, OH),
Circello; Benjamin Thomas (Maineville, OH), Tansky; Cheryl
Sue (Forest Park, OH), Klukowska; Malgorzata (Mason,
OH), Huggins; Thomas Glenn (Mason, OH), Khambe; Deepa
Ashok (Cincinnati, OH), White; Donald James (Fairfield,
OH) |
Applicant: |
Name |
City |
State |
Country |
Type |
The Procter & Gamble Company |
Cincinnati |
OH |
US |
|
|
Assignee: |
The Procter & Gamble
Company (Cincinnati, OH)
|
Family
ID: |
56024418 |
Appl.
No.: |
15/939,382 |
Filed: |
March 29, 2018 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20180231546 A1 |
Aug 16, 2018 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
15148663 |
May 6, 2016 |
9970934 |
|
|
|
62309110 |
Mar 16, 2016 |
|
|
|
|
62157659 |
May 6, 2015 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K
8/42 (20130101); A61K 8/4926 (20130101); A61K
8/21 (20130101); G01N 33/5044 (20130101); A61K
8/361 (20130101); C12Q 1/6897 (20130101); G01N
33/5091 (20130101); A61K 8/0204 (20130101); A61K
8/39 (20130101); G01N 33/5041 (20130101); G01N
33/566 (20130101); G01N 33/579 (20130101); A61Q
11/00 (20130101); G01N 2333/705 (20130101); G01N
2333/70596 (20130101); G01N 2400/50 (20130101); C12Q
2600/136 (20130101); A61K 2800/74 (20130101); G01N
2333/195 (20130101) |
Current International
Class: |
C12Q
1/00 (20060101); G01N 33/566 (20060101); A61Q
11/00 (20060101); A61K 8/49 (20060101); A61K
8/42 (20060101); G01N 33/50 (20060101); C12Q
1/6897 (20180101); G01N 33/579 (20060101); A61K
8/02 (20060101); A61K 8/21 (20060101); A61K
8/36 (20060101); A61K 8/39 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
2323630 |
|
Aug 1990 |
|
CA |
|
1971865 |
|
Apr 2013 |
|
EP |
|
2481267 |
|
Apr 2016 |
|
GB |
|
WO1995013094 |
|
May 1995 |
|
WO |
|
WO2008042279 |
|
Apr 2008 |
|
WO |
|
WO2011091366 |
|
Jul 2011 |
|
WO |
|
WO2014098868 |
|
Jun 2014 |
|
WO |
|
Other References
13837M International Search and Written Opinion for
PCT/US2016/031349 dated Jul. 18, 2016. cited by applicant .
13838M Search Report and Written Opinion for PCT/US2016/031350
dated Jul. 18, 2016. cited by applicant .
Chuang, TH1 et al., "Cloning and characterization of a sub-family
of human toll-like receptors: hTLR7, hTLR8 5 and hTLR9", Eur.
Cytokine Netw.. Sep. 2000, 11(3):372-8). cited by applicant .
Darveau, R.P. et al., "Porphyromonas gingivalis Lipopolysaccharide
Contains Multiple Lipid A species That Functionally Interact with
Both Toll-Like Receptors 2 and 4", Infection and Immunity, vol. 72,
No. 9, Sep. 1, 2004, pp. 5041-5051. cited by applicant .
Dongari-Bagtzoglou et al., "Production of inflammatory mediators
and cytokines by human gingival fibroblasts following bacterial
challenge", J. Periodont. Res. 1996; 31:90-98. cited by applicant
.
Henkel et al. "Toxins from Bacteria", EXS (2010) 100:1-30. cited by
applicant .
Hong, Sun Woong et al., "Lipoteichoic acid of Streptococcus mutans
interacts with Toll-like receptor 2 through the lipid moiety for
induction of inflammatory mediators in murine macrophages",
Molecular Immunology, vol. 57, pp. 284-291, 2014. cited by
applicant .
Huang, Li-Yun et al., "Use of Toll-Like Receptor Assays to Detect
and Identify Microbial Contaminants in Biological Products",
Journal of Clinical Microbiology, Nov. 2009, p. 3427-3434. cited by
applicant .
Liebers, Verena et al. "Occupational Endotoxin-Exposure and
Possible health Effects on Human", American Journal of Industrial
Medicine 49(6):474-491 (2006). cited by applicant .
Madianos, PN et al., "Generation of inflammatory stimuli: how
bacteria set up inflammatory responses in the gingiva", J. Clin.
Periodontol. 2005; 32(supplement 6): 57-71. cited by applicant
.
Mullarkey, M. et al. "Inhibition of endotoxin response by E5564, a
novel toll like receptor 4 directed endotoxin antagonist", Journal
of Pharmacology and Experimental Therapeutics, American Society for
Pharmacologoy and Experimental Therapeutics, vol. 304, No. 3, Jan.
1, 2003, pp. 1093-1102. cited by applicant .
Offenbacher, S et al., "Gingival transcriptome patterns during
induction and resolution of experimental gingivitis in humans", J.
Periodontol. Dec. 2009; 80(12): 1963-82. cited by applicant .
Raetz et al. "Lipopolysaccharide endotoxin", Annu. Rev. Biochem
(2002) 71:635-700. cited by applicant .
Rock, FL et al., "A family of human receptors structurally related
to Drosophila Toll", Proc. National Academy Science, Jan. 20, 1998,
95:588-93. cited by applicant .
Shapira, L. et al., "Effect of Amine- and Stannous Fluoride on
Human Neutrophil Functions in vitro", J. Dent. Res. 73 (7):
1381-1386, Jul. 1997. cited by applicant .
Sulamain, Ali et al. "Corresponding Author: Bacterial Endotoxin
Released by Different Types of Mouthwash", World Applied Sciences
Journal, Jan. 1, 2012, pp. 305-309. cited by applicant .
Takeuchi, et al., "A novel member of an expanding toll-like
receptor family", Gene, Apr. 29, 1999, 231(1-2): pp. 59-65. cited
by applicant .
Wood, Stewart J. et al., "Anti-Endotoxin Agents. 1. Development of
a Fluorescent Probe Displacement Method Optimized for
High-Throughput Identification of Lipopolysaccharide-Binding
Agents", May 1, 2004, retrieved from Internet on Jun. 23, 2016:
URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1540690/pdf/nihms2661.ppd-
f. cited by applicant .
Yokoyama, Yuji et al., "Systemic Immune Response to Streptococcal
and Staphylococcal Lipoteichoic Acids in Children with Recurrent
Tonsillitis", Acta Otolaryngol (Stockh) 1996; Suppl 523: 108-111.
cited by applicant .
Zhang, Hongwei et al., "Lipoprotein Release by Bacteria: Potential
Factor in Bacterial Pathogenesis", Infection and Immunity, Nov.
1998, vol. 66, No. 11, pp. 5196-5201. cited by applicant .
All Office Actions from U.S. Appl. No. 15/148,663, filed May 6,
2016--See Private Pair. cited by applicant .
All Office Actions from U.S. Appl. No. 15/149,044, filed May 6,
2016--See Private Pair. cited by applicant.
|
Primary Examiner: Navarro; Albert M
Attorney, Agent or Firm: McCrary; Parker D.
Claims
What is claimed is:
1. A method of determining bacterial virulence in an oral cavity
comprising: a. providing a reporter cell expressing at least one
toll-like receptor; b. providing a sample of oral matter; c.
combining the sample of oral matter and the reporter cell; d.
measuring the toll-like receptor activation; e. providing another
sample of oral matter from an individual who used an oral care
composition prior to providing another sample of oral matter; f.
combining the another sample of oral matter and the reporter cell;
g. measuring the toll-like receptor response; h. comparing the
toll-like receptor response from the sample of oral matter and
another sample of oral matter.
2. The method of claim 1, wherein the toll-like receptor is at
least one of TLR1 to TLR9.
3. The method of claim 1, wherein the reporter cell expresses at
least of one TLR2 or TLR4.
4. The method of claim 1, wherein the toll-like receptor activates
a reporter gene.
5. The method of claim 4, wherein the reporter gene is a secreted
embryonic alkaline phosphatase (SEAP) reporter gene.
6. The method of claim 1, wherein the sample of oral matter is at
least one of gum-line plaque, subgingival plaque, supragingival
plaque, interstitial plaque, gingival crevicular fluid (GCF),
gingival biopsy, saliva, or tongue swab.
7. The method of claim 1, wherein the sample of oral matter
comprises virulence factor that is at least one of Gram positive
cell wall components, Gram negative cell wall components, bacterial
DNA, flagellin, peptidoglycan, bacterial metabolites, fimbriae;
outer membrane vesicles bacterial proteins, or bacterial
enzymes.
8. The method of claim 7, wherein the sample of oral matter
comprises virulence factor that is at least one of
lipopolysaccharide or lipoteichoic acid.
9. The method of claim 1, where the sample of oral matter and the
another sample of oral matter are from the same individual.
Description
FIELD OF THE INVENTION
The invention relates to a method for detecting and quantifying
bacterial virulence factors in oral samples, and for identifying
agents for detoxifying oral virulence factors and a method for
determining the effectiveness of detoxifying agents.
BACKGROUND OF THE INVENTION
The toxins of bacterial cell walls (Henkel et al, EXS. (2010) 100:
1-29) have been associated with health related issues, such as
septic shock, fever and malaise (V. Liebers et al., Am J Ind Med.
(2006) 49(6): 474-91). Examples of Gram-negative cell wall toxins
associated with health concerns are endotoxins, such as
lipopolysaccharide (LPS), peptidogylcans, and fimbriae; and
Gram-positive cell wall toxins associated with health concerns are
lipoteichoic acid (LTA) and peptidoglycans. There are many other
bacterial toxins, such as enterotoxins and exotoxins, as reported
in Henkel et al, EXS. 2010; 100: 1-29. For the oral environment,
the LPS and LTA seem to be the dominant drivers of a bacterial
induced immune response, or at least the best characterized. The
immune response mounted by the body in response to these toxins
depends on the origin of the toxin and the exposure history of the
individual to said toxin. The LPS is a component of Gram-negative
bacteria that is different from strain to strain, as has been
illustrated with the differences in virulence of E. coli (Raetz and
Whitfield Annu. Rev. Biochem (2002) 71:635-700). LPS is composed of
a lipid A fraction, core region, and may have an O-antigen. The
Lipid A fraction's fatty acid composition has been shown to
determine its virulence in response to its interaction with the
Toll-like 4 (TLR4) receptor. The LTA has been linked to various
inflammatory responses (Y. Yokoyama, et al., Acta Otolaryngol
Suppl. (1996) 523:108-111) and associated with Toll-like receptor 2
(TLR2) activation. It is widely believed that only the lysed
bacteria liberate LPS that can initiate an inflammatory response
(CA2323630). However, Zhang et al. showed that growing bacteria
secrete LPS at a level in proportion to their growth phase (H.
Zhang et al. (1998) Infection & Immunity, 66(11), 5196-5201).
Therefore, even a small fraction of the plaque left on the teeth
after brushing could seed the inflammatory cascade due to the
release of LPS from the Gram negative bacteria present in the
plaque.
Methods of detecting specific microbial species have been
demonstrated in the art. In US Pub. No. 2012/019735A1, methods were
proposed to distinguish disease-causing bacteria via
spectrophotometric methods. Though they were able to show the
presence of specific microbes, their invention would not allow the
user to determine the virulence level of a specific site. Further,
their method requires the microbes to be cultured in the lab in
order to obtain a sufficient quantity of LTA or LPS for detection.
Thus, their invention lacks the ability to detect the
non-culturable species present, nor would it allow for measures of
toxicity of biological samples.
In U.S. Pat. No. 5,175,089, the use of the Limulus amebocyte lysate
(LAL) endotoxin (LPS) assay was applied to the determination of the
amount of endotoxin in the periodontal pocket. Though they were
able to show overall amounts of endotoxin present, they lacked the
ability to differentiate diseased versus healthy endotoxin and they
were unable to quantify the level of virulence of the endotoxin.
Further, their invention limited them to the Gram-negative
endotoxin, as the LTA is not detectable via the LAL kit.
In US Pub. No. 2009/0047240, the chaperonin 10 (Cpn10) was used to
modulate the clustering of Cpn10 in a cell line (murine RAW264)
with labeled antibodies. Though they showed TLR-4, 7, and 9
reporter genes in an HEK cell line, their system would not allow
for a more sensitive or low level detection needed for microbial
populations with weaker activating LPS, since those genes were
under the control of the NFkB binding sites only (a minimal
promoter). Their system lacks the sensitivity needed to
differentiate biological systems with multiple microbial species
and no dominant organism present. Further, their system needs
strong NFkB activators to overcome the weak promoter used in their
system, thus unable to pick up weaker TLR LPS agonists, such as LPS
from Porphyromonas gingivalis. Additionally, their system lacked
the ability to detect TLR3 agonists, which would be deleterious to
the characterization of an inflammatory disease, such as
gingivitis.
US Pub. No. 2007/0160544 describes a method for determining orally
deleterious bacteria. Their method calls for contacting a gingival
cell with bacteria or a bacterial component and measuring an
inflammatory marker. According to US Pub. No. 2007/0160544, the
presence of a marker indicates inflammation and the labeling of a
bacterium as deleterious. Conversely, they say that the absence of
a marker indicates the bacterium is not a problem. Though they
cited Toll-like receptors, which were known in the art as part of
the pathway to generate cytokines, their method would have only
allowed for determining the presence of a cytokine.
Since oral cells contain one or more of the receptors to which a
bacterial virulence factor would activate, screening on the
individual receptors requires the use of engineered cells, such as
reporter cells containing the receptor gene of interest. What
further complicates the use of native oral cells, such as gingival
cells, is that the expression and activation of a receptor, such as
a Toll-like receptor, is specific to the function of the cell.
Gingival cells are less likely to respond to bacterial virulence
factors, due to their constant contact with microbes in the dental
plaque. Thus the need exists to have engineered cells where a
direct response can be measured via a reporter system.
In addition to quantifying the virulence of microbial components
and byproducts, there also exists a need for an in vitro screen of
the inflammatory potential of organic and inorganic molecules,
which would allow for pharmokinetic parameters to be
determined.
SUMMARY OF THE INVENTION
A method of determining bacterial virulence in an oral cavity is
provided that includes providing a reporter cell expressing at
least one toll-like receptor; providing a sample of oral matter;
combining the sample of oral matter and the reporter cell; and
measuring the toll-like receptor activation. The method may also
include the additional steps of providing another sample of oral
matter from an individual who used an oral care composition prior
to providing another sample of oral matter; combining the another
sample of oral matter and the reporter cell; measuring the
toll-like receptor response; and comparing the toll-like receptor
response from the sample of oral matter and another sample of oral
matter.
A method for determining the virulence of lipopolysaccharide
comprising providing a lipopolysaccharide; providing a reporter
cell expressing at least one Toll-like receptor; combining the
reporter cell with the lipopolysaccharide; measuring the toll-like
receptor activation; and quantifying the lipopolysaccharide.
A method for determining the virulence of lipoteichoic acid
comprising providing a lipoteichoic acid; providing a reporter cell
expressing at least one Toll-like receptor; combining the reporter
cell with the lipoteichoic acid; measuring the toll-like receptor
activation; and quantifying the lipoteichoic acid.
The present invention includes methods of improving and/or
resolving the state of gingival inflammation utilizing molecules,
peptides, or proteins/enzymes that bind to, alter, or chemically
modify bacterial virulence factors and/or host response mechanisms.
The methods provide a means of quantifying the level of
lipopolysaccharide of oral tissues; and utilizes TLR-4 and TLR-2
reporter cells line combined with the detection LPS via a
fluorescence assay, such as BODIPY TR cadaverine, or endotoxin
detection assay, assay to assign potency and quantification of LPS.
The invention also includes assays and protocols which enable
communication and demonstrations to consumers and dental
professionals utilizing the TLR reporter cells.
The present invention includes methods for determining the potency
of lipopolysaccharide comprising: a) providing a lipopolysaccharide
sample; b) providing reporter cells expressing one or more
Toll-like receptors; c) exposing the cells to the
lipopolysaccharide sample; d) measuring the EC50 value of the
lipopolysaccharide on activation of a Toll-like receptor; e)
quantification of the lipopolysaccharide.
The present invention also includes isolating lipopolysaccharide
from a growth culture of Gram negative bacteria. A
lipopolysaccharide may be isolated from a biological sample. The
biological sample includes, but is not limited to, an oral plaque,
saliva, gingival brush samples. Toll-like receptor reporter gene
assays, such as TLR4-SEAP and/or TLR2-SEAP, may be used to detect
and quantify bacterial toxins, including but not limited to
endotoxins, in a biological sample.
A BODIPY TR cadaverine assay may be used to detect and quantify
lipopolysaccharide in a biological sample. In addition, LAL (the
Limulus amebocyte lysate assay) assay or endotoxin detection assay
may be used to detect and quantify the lipopolysaccharide in a
biological sample.
The present invention may be directed toward a method for
determining the potency of an oral biofilm comprising: a) providing
a biofilm sample; b) providing reporter cells expressing one or
more Toll like receptors; c) exposing the cells to the biofilm
sample; d) measuring the EC50 value of the biofilm activation of a
Toll like receptor; e) quantification of the lipopolysaccharide.
The biofilm may be an oral plaque, including but not limited to
subgingival plaque, marginal or gumline plaque, supragingival
plaque.
The present invention may also be directed toward a method for
determining the potency of virulence in an oral sample comprising:
a) providing an oral sample; b) providing reporter cells expressing
one or more Toll-like receptors; c) exposing the cells to the oral
sample; d) measuring the EC50 value of the biofilm activation of a
Toll like receptor; e) quantification of the lipopolysaccharide.
The oral sample may include saliva, oral lavage or gingival
crevicular fluid.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1A is a graph showing secretion of LPS during bacterial growth
in culture.
FIG. 1B is a graph showing time course of bacterial growth in
culture medium.
FIG. 1C is a graph showing secretion of LPS during bacterial growth
in culture.
FIG. 1D is a graph showing secretion of LPS during bacterial growth
in culture at 24 hours. P. pallens and P. nigrescens released more
LPS into the medium than P gingivalis.
FIG. 1E is a graph showing the amount of LPS per bacterium during
bacterial growth in culture at 24 hours. P. pallens and P.
nigrescens contain more LPS than P gingivalis.
FIG. 1F is a picture showing the taking of gingival plaque samples
using Periopaper.
FIG. 2A is a graph showing cell culture and virulence determination
of lipopolysaccharide from different bacteria.
FIG. 2B is a graph showing activation of TLR4 reporter gene in
culture.
FIG. 2C is a graph showing activation of TLR4 reporter gene in
culture.
FIG. 3 is a graph showing stannous fluoride inhibition of TLR4
reporter gene expression.
FIG. 4 is a graph showing stannous fluoride prevention of P.
gingivalis LPS from activating TLR2 reporter gene expression.
FIG. 5 is a graph showing percentage reduction of P. gingivalis LPS
on activation of TLR-4 by stannous fluoride.
FIG. 6 is a graph showing EC50 determination of subgingival plaques
that activate TLR4-SEAP signal transduction. Dental plaques from
unhealthy sites had a smaller EC50 than those from healthy sites,
suggesting the dental plaques from unhealthy sites contain more
virulence factors.
FIG. 7A is a graph showing TLR4 Evaluation of Human Subgingival
Plaque (Healthy vs. Gingivitis).
FIG. 7B is a graph showing TLR4 Evaluation of Human oral lavage
(Healthy vs. Gingivitis). and
FIG. 8A is a graph showing cell culture and virulence determination
of LTA from different bacteria.
FIG. 8B is a graph showing cell culture and virulence determination
of LPS from different bacteria.
FIG. 8C is a graph showing cell culture and virulence determination
of LPS from different bacteria.
FIG. 8D is a graph showing cell culture and virulence determination
of LPS from different bacteria.
FIG. 9 is an EC50 graph showing determination of subgingival
plaques that activate TLR2-SEAP signal transduction.
FIG. 10A is a graph showing TLR2 Evaluation of Human Subgingival
Plaque (Healthy vs. Gingivitis).
FIG. 10B is a graph showing TLR2 Evaluation of Human oral lavage
(Healthy vs. Gingivitis).
FIG. 11 is a graph showing cell culture and virulence determination
of flagellins from different bacteria.
FIG. 12A is a graph showing LPS Stimulated TLR Activity in Human
Monocytes THP-1.
FIG. 12B is a graph showing Evaluation of Human oral lavage
(Healthy vs. Gingivitis) using the IRF-Luc reporter gene in THP-1
cells.
FIG. 12C is a graph showing Evaluation of Human Subgingival Plaque
(Healthy vs. Gingivitis) in THP-1 cells using the NFkB reporter
gene.
FIG. 13 is a graph showing detection of LTA of different bacteria
in THP1 dual reporter cells.
FIG. 14 is a graph showing clinical measurements.
FIG. 15 is graphs showing decreases in bacterial abundance in the
supragingival plaques during six weeks of regimen treatment.
FIG. 16 is a graph showing citrulline concentrations in
Buccal-brush samples over a six-week regimen treatment.
FIG. 16A is a figure showing the relationship between FIG. 16A-1,
FIG. 16A-2, and FIG. 16A-3.
FIG. 16A-1 is graphs showing decreases in bacterial abundance in
the supragingival plaques during six weeks of regimen
treatment.
FIG. 16A-2 is graphs showing decreases in bacterial abundance in
the supragingival plaques during six weeks of regimen
treatment.
FIG. 16A-3 is graphs showing decreases in bacterial abundance in
the supragingival plaques during six weeks of regimen
treatment.
FIG. 17 is a graph showing protein bound ornithine in Buccal brush
samples during treatment.
FIG. 18 is a diagram showing enzymes in the ornithine, citrulline
and arginine cycle.
FIG. 19 is a graph showing expression of ornithine, citrulline and
arginine genes during a 6-week treatment.
FIG. 20 is a graph showing citrulline concentrations increased in
Buccal-brush samples in experimental gingivitis.
FIG. 21 is graphs showing protein bound citrulline in Buccal brush
samples in experimentally induced gingivitis.
FIG. 22 is graphs showing concentrations of protein bound ornithine
in Buccal-brush samples in experimentally induced gingivitis.
FIG. 23 is graphs showing concentrations of total ornithine in
Buccal-brush samples in experimentally induced gingivitis.
FIG. 24 is graphs showing concentrations of protein bound arginine
in Buccal-brush samples in experimentally induced gingivitis.
FIG. 25 is a graph showing concentrations of total arginine in
Buccal-brush samples in experimentally induced gingivitis.
FIG. 26 is a graph showing citrulline inhibited cytokine production
stimulated by P. gingivalis LPS 1690 in THP-1 cells.
FIG. 27 is graphs showing bacterial LTA reduces fluorescent
intensity of BC in a dose dependent manner.
FIG. 28 is graphs showing LPS reduces the fluorescent intensity of
BC in a dose-dependent manner.
FIG. 29 is graphs showing the supernatant of bacterial culture
reduces the fluorescent intensity of BC in a dose-dependent
manner.
FIG. 30 is graphs showing bacteria reduce the fluorescent intensity
of BC in a dose-dependent manner.
FIG. 31 is graphs showing EC50 values.
DETAILED DESCRIPTION OF THE INVENTION
As disclosed herein, it was surprisingly discovered that one or
more methods could be used to detect and quantify the virulence in
subgingival and supragingival plaques, thus distinguishing healthy
gingivae from an inflamed site suffering from the symptoms of
gingivitis. The state of health of the gingivae can be directly
related to the level of bacterial toxins present, for example,
endotoxins, and thus a reduction of these toxins, as discussed
herein, in the oral cavity, as determined by screening on
non-gingival engineered cells, would improve overall oral health.
Additionally, the way an individual responds to the virulence
factors can be quantified utilizing the individual's metabolic
pathways, such as by quantifying products of the urea cycle.
Gingivitis is defined per the FDA monograph (12 CFR Part 356, Vol.
68, No. 103 (2003)) as "An inflammatory lesion of the gingiva that
is most frequently caused by dental plaque. Gingivitis is
characterized by tissue swelling and redness, loss of stippling (a
normal state in which the surface of healthy gingiva is comprised
of small lobes), glossy surface, and increased tissue temperature.
The gingiva also may bleed upon gentle provocation, such as tooth
brushing or may bleed spontaneously. Gingivitis is usually not
painful." Within the monograph, plaque is defined as being composed
of multiple bacterial species. Those species exert a constant
inflammatory pressure on the host tissues.
When the inflammation progresses to the state of gingivitis, there
exists a need to quantify how severe the gingivitis is and how
effective treatments from oral hygiene products are in reducing the
inflammatory response. The reduction in inflammatory response due
to activation of membrane bound receptors across the gingival cells
is termed detoxification; and measuring the level of
detoxification, which is lacking in the art, is needed to educate
consumers on the efficacy of their oral hygiene.
Pathogenesis of gingivitis involves both bacteria and host
responses. The present invention discloses methodologies measuring
the virulence factors in the dental plaques in vitro, and also
measuring effects of virulence factors on gingival tissues in vivo.
These methodologies allow understanding of what virulence factor
types are present in the dental plaques, and how the host responds.
Importantly, the measuring of virulence factors provides a detailed
assessment on the severity of gingivitis in terms of virulence
factors of the microbes in dental plaques and the health status of
the host. In addition, these methods help evaluate the
effectiveness of a technology in preventing and treating
gingivitis.
The present invention includes a methodology comprising one or more
of the following steps: (1) using the endotoxin detection assay kit
or BODIPY-TR cadaverine method to quantify total LPS and LTA
present in a biological sample and to detect technologies that
inhibit the endotoxin detection assay; (2) using the Toll like
receptor assays to determine potency of purified virulence and oral
dental plaques, and to measure the efficacy of technologies that
neutralize toxicity of virulence factors; (3) using meta-sequencing
to identify and quantitate bacteria in supragingival plaques, (4)
measuring ornithine and citrulline in gingival swab samples to
determine the healthy status of gingival tissue, (5) measuring
protein and mRNA levels to determine the levels of host responses,
and determining citrulline activities in inhibiting LPS-induced
production of proinflammatory cytokines.
The above-mentioned methods and chemistry may be applied in a strip
form to the outer surface of the tooth and gumline. The strip may
contain color or fluorescence reagents to interact with the
virulence factors present and thus allow for semi-quantitative
determination of the virulence present.
This would allow for rapid assessment of the level of severity of
gingivitis and/or periodontal disease or to ascertain the
effectiveness of oral products. This execution of the described
methods allows for consumers to ascertain the state of their dental
health at home or allows for professionals, such as dentists, to
rapidly measure the state of a patient's oral health.
The methods described above can be used to determine the cellular
impact of organic and inorganic molecules, as long as there is an
interaction between the molecule and the targeted receptor.
Further, the methods could be used to ascertain if a molecule would
cause an irritation or inflammatory response. The receptor in
question would be used in a reporter system, as described herein,
and the molecular impact of the molecule in question determined.
The EC50 value of the molecule in question would be determined
using the receptor associated with the biological response, thus
reducing or eliminating the need to do animal testing.
All percentages and ratios used hereinafter are by weight of total
composition, unless otherwise indicated. All percentages, ratios,
and levels of ingredients referred to herein are based on the
actual amount of the ingredient, and do not include solvents,
fillers, or other materials with which the ingredient may be
combined as a commercially available product, unless otherwise
indicated.
All measurements referred to herein are made at 25.degree. C. (i.e.
room temperature) unless otherwise specified
As used herein, the word "include," and its variants, are intended
to be non-limiting, such that recitation of items in a list is not
to the exclusion of other like items that may also be useful in the
materials, compositions, devices, and methods of this
invention.
As used herein, the word "or" when used as a connector of two or
more elements is meant to include the elements individually and in
combination; for example X or Y, means X or Y or both.
By "personal care composition" is meant a product, which in the
ordinary course of usage is applied to or contacted with a body
surface to provide a beneficial effect. Body surface includes skin,
for example dermal or mucosal; body surface also includes
structures associated with the body surface for example hair,
teeth, or nails. Examples of personal care compositions include a
product applied to a human body for improving appearance,
cleansing, and odor control or general aesthetics. Non-limiting
examples of personal care compositions include hair coloring
compositions, oral care compositions, after shave gels and creams,
pre-shave preparations, shaving gels, creams, or foams,
moisturizers and lotions, cough and cold compositions, leave-on
skin lotions and creams, shampoos, conditioners, shower gels, bar
soaps, toilet bars, antiperspirants, deodorants, depilatories,
lipsticks, foundations, mascara, sunless tanners and sunscreen
lotions.
By "oral care composition", as used herein, is meant a product,
which in the ordinary course of usage, is not intentionally
swallowed for purposes of systemic administration of particular
therapeutic agents, but is rather retained in the oral cavity for a
time sufficient to contact dental surfaces or oral tissues.
Examples of oral care compositions include dentifrice, mouth rinse,
mousse, foam, mouth spray, lozenge, chewable tablet, chewing gum,
tooth whitening strips, floss and floss coatings, breath freshening
dissolvable strips, or denture care or adhesive product. The oral
care composition may also be incorporated onto strips or films for
direct application or attachment to oral surfaces.
The term "dentifrice", as used herein, includes tooth or
subgingival-paste, gel, or liquid formulations unless otherwise
specified. The dentifrice composition may be a single phase
composition or may be a combination of two or more separate
dentifrice compositions. The dentifrice composition may be in any
desired form, such as deep striped, surface striped, multilayered,
having a gel surrounding a paste, or any combination thereof. Each
dentifrice composition in a dentifrice comprising two or more
separate dentifrice compositions may be contained in a physically
separated compartment of a dispenser and dispensed
side-by-side.
The term "teeth", as used herein, refers to natural teeth as well
as artificial teeth or dental prosthesis.
Virulence factors are molecules produced by pathogenic microbes
that contribute to the pathogenicity of the organism and enable
them to invade and proliferate in the host, and evade host immune
surveillance. Virulence factors include, but are not limited to the
following: Gram positive and Gram negative cell wall components,
such as lipopolysaccharide and lipoteichoic acids, bacterial DNA,
flagellin, peptidoglycan, adhesins, invasins, and antiphagocytic
factors, hemolysins, bacterial metabolites, fimbriae, outer
membrane vesicles, bacterial proteins or bacterial enzymes. A
reduction in virulence or "detoxification", based on reduced
activation of Toll-like receptors, can be used to measure the
effectiveness of various treatments.
The term "detoxification" or "detoxify" or "detox" as used herein,
refers to the neutralization, reduction, or removal of microbial
virulence factors as measured by a reduction in the activation of a
receptor known to be responsive with a virulence factor from an
engineered cell, such as a reporter cell line. In certain
embodiments a determination of virulence is assigned based on the
activation of one or more of the Toll-like receptors.
The present invention includes obtaining a sample of oral matter.
The oral matter can include gum-line plaque, subgingival plaque,
supragingival plaque, interstitial plaque, gingival crevicular
fluid (GCF), gingival biopsy, saliva, or tongue swab. The oral
matter may be obtained by any method known in the art, for example,
subgingival plaque sample may be collected physically by scraping
or by using paper points. The plaque may be collected off of the
tooth beneath gums from the sulcus, the developed periodontal
pocket, or at the gumline. For example, each paper point can be
placed in the pocket between the tooth and the gingiva for 10
seconds. After 10 seconds, a paper point can be removed and placed
into a pre-labeled 1.5 ml tube with 700 .mu.l phosphate-buffered
saline. The sampling procedure can be repeated with three more
paper points. After all four paper points are collected, the 1.5 ml
tube will be closed, vortexed for 30 seconds and placed on dry ice
until the samples are stored in a -80.degree. C. freezer. Other
methods of collection could include a mechanical device to help
release the plaque from the tooth surface, such as a sonic
descaler. The oral matter may be obtained both before and after
treatment of an oral site from which the oral matter is obtained.
An oral site from which the oral matter is obtained includes host
tissues and bacterial matters. Further treatment of an oral site
may be more than once and may include multiple different
treatments, for example a regimen, such as brushing teeth followed
by mouthrinse. In addition to obtaining oral matter before and
after completed treatments, oral matter may be obtained between
separate treatments, for example between the brushing of teeth
followed by the use of mouth rinse.
The sample of oral matter is combined with a Toll-like receptor in
a reporter cell. Examples of Toll-like Receptors that can be used
in the present invention include TLR 2, TLR 4, TLR 5, and TLR 9.
Human TLR cDNA (TLR 1, 2, 3, 4, and 5) was first cloned in 1998 and
their sequences were published (Rock F L, Hardiman G, Timans J C,
Kastelein R A, Bazan J F. A family of human receptors structurally
related to Drosophila Toll. Proc Natl Acad Sci USA. 1998 Jan. 20;
95:588-93). Rock et al. discovered that cytoplasmic domains of
Drosophila Toll and human interleukin 1 receptors shared high
sequence homology, and hypothesized that both molecules trigger
related signaling pathways tied to the nuclear translocation of
Rel-type transcription factors. They cloned a class of putative
human receptors with a protein architecture that is similar to
Drosophila Toll in both intra- and extracellular segments. They
hypothesized that the five human Toll-like receptors--named TLRs
1-5--are probably the direct homologs of the fly molecule and, as
such, could constitute an important and unrecognized component of
innate immunity in humans. Soon after the DNA sequences for TLR1 to
5 were published, other TLR DNA sequences were also revealed. For
example, TLR6 cDNA sequence was reported in 1999 (Takeuchi O1,
Kawai T, Sanjo H, Copeland N G, Gilbert D J, Jenkins N A, Takeda K,
Akira S. A novel member of an expanding toll-like receptor family.
Gene. 1999 Apr. 29; 231(1-2):59-65). cDNA sequences of human TLR7,
TLR8 and TLR9 were reported in 2000 (Chuang TH1, Ulevitch R J.
Cloning and characterization of a sub-family of human toll-like
receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw. 2000
September; 11(3):372-8).
TABLE-US-00001 SEQ ID NO Sequence 1 Human Toll-Like Receptor 1
Amino Acid sequence 2 Human Toll-Like Receptor 2 Amino Acid
sequence 3 Human Toll-Like Receptor 3 Amino Acid sequence 4 Human
Toll-Like Receptor 4 Amino Acid sequence 5 Human Toll-Like Receptor
5 Amino Acid sequence 6 Human Toll-Like Receptor 6 Amino Acid
sequence 7 Human Toll-Like Receptor 7 Amino Acid sequence 8 Human
Toll-Like Receptor 8 Amino Acid sequence 9 Human Toll-Like Receptor
9 Amino Acid Sequence
A sequence listing that sets forth the amino acid sequences for SEQ
ID NO: 1 to 9 herein is being filed concurrently with the present
application as an ASCII text file titled
"13837M_AA_Sequence_Listing_ST25." The ASCII text file was created
on 29 Mar. 2016 and is 68 Kbytes in size. In accordance with MPEP
.sctn. 605.08 and 37 CFR .sctn. 1.52(e), the subject matter in the
ASCII text file is incorporated herein by reference.
TLR proteins can form heterodimers or homodimers. There are 10 TLR
genes identified in humans. Their gene products form homodimers or
heterodimers in cell membranes. For example, TLR1 can form
heterodimers with TLR. Similarly, TLR6 also can assemble a
heterodimer with TLR2. On other hand, TLR4 forms a homodimer.
Toll-like receptors (TLRs) are a class of proteins that play a key
role in the innate immune system as well as the digestive system.
They are membrane-spanning, non-catalytic receptors usually
expressed in cells such as macrophages, dendrite cells, and
gingival epithelial cells that recognize structurally conserved
molecules derived from microbes. Once these microbes have breached
physical barriers such as the skin or intestinal tract mucosa or
oral epithelial cells they are recognized by TLRs, which activate
immune cell responses. Toll-like receptors were targeted because
they are the primary sensors of virulence factors produced by the
microbes in the dental plaques. TLR 1, 2, 4, 5 and 6 are expressed
in the cell plasma membranes, providing easy access for the
virulence factors to be sensed by the host receptors. TLR 3, 7, 8,
and 9 are located on the membranes of endosomes; and as virulence
factors are phagocytosed into the cells, they also gain access to
TLR 3, 7, 8 and 9
A reporter cell refers to a eukaryotic cell, such as, but not
limited to, HEK 293T, human monocyte (THP1), Chinese hamster ovary
(CHO) cell, murine cells, or monkey kidney epithelial (Vero) cells
engineered to express a predetermined number of TLR receptors, for
example a single TLR receptor; which is in contrast to gingival
cells that express multiple functional TLR receptors. Thus, one
type of engineered reporter cells respond to only one type of
virulence factors in the dental plaques. In contrast, gingival
cells express several types of functional TLRs, and can't be used
to identify a single type of virulence factor in dental plaques.
The output from gingival cells is the sum of various virulence
factors in the dental plaques. HEK 293T cells can be used as
reporter cells, as they are easy to maintain and have similar gene
expression profiles to oral epithelial cells, making them a closer
match to the gene expression of gingival cells, such that the
results will mirror in vivo results. In contrast to naturally
occurring gingival cells the reporter cells of the present
invention are easy to maintain in the lab, and stable in
phenotypes. Further, the reporter cells make detection of virulence
factors simpler, are more reproducible, increase accuracy, provide
higher throughput are more specific and more quantifiable.
Individual TLR receptor genes are stably transfected to HEK 293
cells as described by Invivogen (/PDF/HEK_Blue_htlr4_TDS.pdf).
HEK-Blue.TM. hTLR4 Cells are designed for studying the stimulation
of human TLR4 (hTLR4) by monitoring the activation of NF-kB.
HEK-Blue.TM. hTLR4 Cells were obtained by co-transfection of the
hTLR4 gene, the MD-2/CD14 co-receptor genes and a secreted
embryonic alkaline phosphatase (SEAP) reporter gene into HEK293
cells. The SEAP reporter gene is placed under the control of an
IL-12 p40 minimal promoter fused to five NF-kB and AP-1-binding
sites (Supplement 1. HEK-Blue.TM. hTLR4 Cells SEAP Reporter 293
cells expressing the human TLR4 gene, Catalog # hkb-htlr4, Version
#15C04-MM (/PDF/HEK_Blue_htlr4_TDS.pdf). As compared to measuring
an immune response the reporter genes of the present invention
allow rapid, specific and reproducible measurements of virulence
factors.
The level of receptor activation can be determined by any method
known in the art for the type of reporter gene used. For example if
an NFkB-SEAP reporter gene is used, one could measure the
production of SEAP in the culture medium. The reporter cells can be
treated with virulence factors, or dental plaque matters collected
before or after treatments. Expression of the reporter gene will be
stimulated and SEAP secreted into the medium when stimulated by
virulence factors. The level of reporter gene product SEAP can be
readily measured with commercial kits, and will be proportional to
the amount of particular types of virulence factors. Similarly, if
an NFkB-luciferase, NFkB-beta-lactamase, or other reporter genes
are used, available kits can be used to measure the reporter gene
products.
The potency can then be determined based on parameters such as,
EC50 and fold of stimulation. EC50 provides a measurement on the
amount of virulence factors needed to mount an inflammatory
response, and the fold of stimulation is indicative of the severity
of inflammatory responses the virulence factors cause. The EC50 is
used to determine potency; wherein "potency" as defined by the
Merck Manual, refers to the concentration (EC50) of a chemistry
required to produce 50% of the chemistry's maximal effect as
depicted by a graded dose-response curve. EC50 equals Kd
(Dissociation constant, which is a measure of 50% of the substance
in question bound to the receptor) when there is a linear
relationship between occupancy and response. Often, signal
amplification occurs between receptor occupancy and response, which
results in the EC50 for response being much less (ie, positioned to
the left on the abscissa of the log dose-response curve) than Kd
for receptor occupancy. Potency depends on both the affinity of a
compound for its receptor, and the efficiency with which a
compound-receptor interaction is coupled to response. The dose of a
compound required to produce an effect is inversely related to
potency. In general, low potency is important only if it results in
a need to administer a compound in large doses that are
impractical. Quantal dose-response curves provide information on
the potency of a compound that is different from the information
derived from graded dose-response curves. In a quantal
dose-response relationship, the EC50 is the dose at which 50% of
individuals exhibit the specified quantal effect.
In the present invention, the activities of endotoxins or
lipopolysaccharides can be measured using an endotoxin detection
assay, or LAL assay. The Limulus Amebocyte Lysate (LAL) test has
been used to detect LPS. LAL is derived from the blood cells, or
amebocytes, of the horseshoe crab, Limulus polyphemus. At present,
some main endotoxin detection agents are derived from recombinant
proteins. Thereinafter, endotoxin detection assay and LAL assay are
used interchangeably. A. A method of determining bacterial
virulence in an oral cavity comprising: a. providing a reporter
cell expressing at least one toll-like receptor; b. providing a
sample of oral matter; c. combining the sample of oral matter and
the reporter cell; d. measuring the toll-like receptor activation.
B. The method of paragraph A, wherein the toll-like receptor is at
least one of TLR1 to TLR9. C. The method according to paragraph A
or B, wherein the reporter cell expresses at least of one TLR2 or
TLR4. D. The method according to any one of paragraphs A to C,
wherein the toll-like receptor activates a reporter gene,
preferably wherein the reported gene is a secreted embryonic
alkaline phosphatase (SEAP) reporter gene. E. The method according
to any one of paragraphs A to D, wherein the sample of oral matter
is at least one of gum-line plaque, subgingival plaque,
supragingival plaque, interstitial plaque, gingival crevicular
fluid (GCF), gingival biopsy, saliva, or tongue swab, preferably
wherein the sample of oral matter comprises virulence factor that
is at least one of Gram positive cell wall components, Gram
negative cell wall components, bacterial DNA, flagellin,
peptidoglycan, bacterial metabolites, fimbriae; outer membrane
vesicles bacterial proteins, or bacterial enzymes. F. The method of
paragraph E, wherein the sample of oral matter comprises virulence
factor that is at least one of lipopolysaccharide or lipoteichoic
acid. G. The method according to any of paragraphs A to F
comprising the additional steps of: e. providing another sample of
oral matter from an individual who used an oral care composition
prior to providing another sample of oral matter; f. combining the
another sample of oral matter and the reporter cell; g. measuring
the toll-like receptor response; h. comparing the toll-like
receptor response from the sample of oral matter and another sample
of oral matter. H. The method of paragraph G, where the sample of
oral matter and the another sample of oral matter are from the same
individual. I. A method for determining the virulence of
lipopolysaccharide comprising: a. providing a lipopolysaccharide;
b. providing a reporter cell expressing at least one Toll-like
receptor; c. combining the reporter cell with the
lipopolysaccharide; d. measuring the toll-like receptor activation;
e. quantifying the lipopolysaccharide. J. The method of paragraph
I, wherein the Toll-like receptor activation is determined by
measuring at least one of EC50 or fold of stimulation. K. The
method according to paragraph I or J, wherein the Toll-like
receptor is at least one of TLR1 to TLR9. L. The method according
to any of paragraphs I to K, wherein the reporter cell expresses at
least one of TLR2 or TLR4. M. The method according to any of
paragraphs I to L, wherein the Toll-like receptor activates a
reporter gene. N. The method according to paragraph M, wherein the
reported gene is a secreted embryonic alkaline phosphatase (SEAP)
reporter gene. O. The method according to any of paragraphs I to N,
wherein the lipopolysaccharide is quantified using at least one of
limulus amebocyte lysate assay or BODIPY TR cadaverine assay.
EXAMPLES
Example 1--Determination of Secreted Lipopolysaccharide by
Bacteria
Growth of bacteria: A 1 ml aliquot of a 24 hour culture of E. coli
ATCC 8739 was used to inoculate 100 ml of Luria-Bertani (LB) broth
in a 250 ml baffled flask. This culture was then incubated at
37.degree. C. with agitation (220 rpm) and sampled at 30 minute
intervals. Samples were assessed for turbidity (OD.sub.600) in a
SpectraMax platereader M3 (Molecular Devices, Sunnydale, Calif.),
which is one method of monitoring the growth and physiological
state of microorganisms. The sample turbidity was then recorded and
the samples were centrifuged at 5000 RPM for 10 min at room
temperature. The supernatant, thereinafter referred to as
"supernatant of bacterial culture", was subsequently analyzed for
LPS content using the procedure as described below.
Twenty ml aliquots of MTGE broth (Anaerobe Systems, Morgan Hill,
Calif.) were inoculated with P. gingivalis ATCC 33277, P. pallens
ATCC 700821, or P. nigrescens ATCC 25261. These cultures were
incubated overnight in a Whitely A45 Anaerobic Workstation (Don
Whitley Scientific, Frederick, Md.) at 37.degree. C. with an
85:10:5 N.sub.2:CO.sub.2:H.sub.2 gas ratio. One ml aliquots of
these starter cultures were then used to inoculate 99 ml of
membrane-Tryptone Glucose Extract (m-TGE) broth in a 250 ml baffled
flask. These cultures were then incubated under agitation (200 rpm)
as previously described and sampled at regular intervals. Samples
were assessed for turbidity (OD.sub.600) in a Tecan Infinite m200
Pro (Tecan Trading AG, Switzerland) and then centrifuged at
16,100.times.g for 10 min at room temperature. Supernatants were
decanted and passed through a 0.22 .mu.M filter prior to analysis
for LPS content.
In the experiment, only OD600 was measured. For the sake of
consistency in following experiments, we converted OD600 readings
into bacterial numbers, even though the relationship between OD600
readings and bacterial numbers is varied for each bacterium. The
number of bacteria was estimated based on spectrophotometer
readings at OD.sub.600 (OD.sub.600 of 1.0=8.times.10.sup.8
cells/ml).
The Limulus Amebocyte Lysate Assay (LAL) is an assay to determine
the total amount of lipopolysaccharide (LPS) in the sample tested
(Pierce LAL Chromogenic Endotoxin Quantitation Kit, ThermoFischer
Scientific, Waltham, Mass.). The assay was performed following
manufacturer's instruction. Ninety-six-well microplates were first
equilibrated in a heating block for 10 min at 37.degree. C. Fifty
.mu.l each of standard or sample was dispensed into the microplate
wells and incubated with plate covered for 5 min at 37.degree. C.
Then 50 .mu.l LAL was added to each well. Plates were shaken gently
and incubated for 10 min at 37.degree. C. 100 .mu.l of chromogenic
substrate was added and incubated for 6 min at 37.degree. C.
Finally, 50 .mu.l Stop Reagent was added and the absorbance was
measured at 405-410 nm on Spectramax M3 platereader (Molecular
Device, Sunnyvale, Calif.).
FIGS. 1A, 1C, and 1D show the ability of microbes to shed LPS as
part of their normal growth cycle. This data shows the need to
deliver chemistry to the subgingival plaque to effectively mitigate
the LPS, since tooth brushing generally does not remove the
subgingival plaque.
The LPS, as measured by the LAL kit reported in endotoxin unit per
ml (EU/ml), was shed by the bacteria (E. coli K12) as depicted in
FIG. 1A. The growth media began to be depleted of complex sugars
around 120 minutes, as reflected in the bacterial growth curve in
FIG. 1B, where the LPS shedding started to decline. This data gave
a reason to believe that a mature biofilm/plaque could supply a
constant level of LPS to the host cells, if food sources were
present. The LPS would then have the ability to induce an
inflammatory response from the host cells.
Importantly, LPS are secreted into the supernatant of bacterial
culture (FIG. 1D). LPS also exists in bacterial walls (FIG. 1E).
Again, this data further enforce the need to deliver chemistry to
the subgingival plaque to effectively mitigate the LPS, since tooth
brushing generally does not remove the subgingival plaque.
Example 2--LAL Assay to Quantify Virulence Factors in Dental
Plaques
Seven panelists, with at least three bleeding sites, took part in
the testing. A licensed dental hygienist collected subgingival
plaque samples. Samples were taken at the tooth/gum interface
(buccal surfaces only) using care to avoid contact with the oral
soft tissues. Six subgingival plaque sites were sampled from each
panelist (3 healthy and 3 unhealthy sites). Unhealthy teeth had
bleeding sites with pockets greater than 3 mm and healthy sites had
no bleeding with pocket depth less than 2 mm Prior to sampling,
panelists were instructed to abstain for 12 hours from oral hygiene
and refrain from eating, chewing gum, drinking (except small sips
of water). Next, panelists had their marginal plaque collected with
a curette at the sampling sites. Then, from the same site,
subgingival plaque samples were collected with 3 consecutive paper
points as shown in FIG. 1F. The sampling sites were isolated with
cotton rolls and gently air-dried. Paper points (PROFLOW
incorporated, Amityville, N.Y.) were gently placed for 10 seconds
into the pocket until a minimum of resistance was felt. After 10
seconds, paper points were removed and placed into pre-labeled 1.5
ml tubes. The same sampling procedure was repeated with 2 more
paper points (paper points go into separate tubes). The first,
second and third sample paper points from a healthy site of all
panelists were pooled separately into three tubes, labeled as paper
point 1, 2 and 3, respectively. Similarly the unhealthy site
samples were also pooled.
TABLE 1 showed that unhealthy dental plaques contained more
endotoxins than the healthy dental plaques. One m1 PBS was added to
each pooled sample in the 1.5 ml tube. Bacteria were lysed in a
MolBio Fast Prep bead beater (MP Biomedicals, Santa Ana, Calif.).
Samples were centrifuged for 10 min at 10,000 RPM at 4.degree. C.,
supernatants were collected and analyzed with LAL assay kits
following manufacturer's instruction as described in EXAMPLE 1.
TABLE-US-00002 TABLE 1 Protein concentrations and endotoxin levels
in the pooled dental plaque samples. Endotoxin Dental plaque
(endotoxin unit) Healthy paperpoint 1 sub plaque 1284 Healthy
paperpoint 2 sub plaque 476 Healthy paperpoint 3 sub plaque 361
Healthy Marginal Plaque 23180 Unhealthy paperpoint 1 sub plaque
3371 Unhealthy paperpoint 2 sub plaque 1732 Unhealthy paperpoint 3
sub plaque 16111 Unhealthy Marginal Plaque 80277
It was expected that the marginal plaques in unhealthy sites had
more endotoxins than those in the healthy sites (TABLE1) within the
same subjects. Three samples were taken from subgingival pockets
with three paper points sequentially, named paper point 1, 2 and 3.
Again, the subgingival plaques taken by the paper point 1 had more
endotoxins in the unhealthy sites than in the healthy sites (TABLE
1). The same is true for the samples taken by paper point 2 and 3.
Importantly, dental plaques in the unhealthy subgingival pockets
possessed more endotoxins than plaques from healthy pockets. This
may explain why unhealthy gingiva are prone to bleeding upon
probing.
Example 3--Technology Development Using the LAL Assay Kit
The LAL assay, as described in EXAMPLE 1, was modified for
development of technology which inhibits LPS from activating a
proenzyme in the LAL assay. The Thermo Scientific Pierce LAL
Chromogenic Endotoxin Quantitation Kit is a quantitative endpoint
assay for the detection of LPS, which catalyzes the activation of a
proenzyme in the modified Limulus Amebocyte Lysate (LAL). The
activated proenzyme then splits p-Nitroaniline (pNA) from the
colorless substrate, Ac-Ile-Glu-Ala-Arg-pNA. The product pNA is
photometrically measured at 405-410 nm. If SnF2 binds to LPS, the
latter can't react with the proenzyme in the LAL kit. Consequently,
the proenzyme is not activated, and the colorless substrate
Ac-Ile-Glu-Ala-Arg-pNA will not split and no color product is
produced. P. gingivalis LPS 1690 (1 ng/ml), or E. coli LPS (1
ng/ml), and stannous fluoride and other materials (50 and 500
.mu.M), as listed in TABLE 2, were dissolved in endotoxin-free
water. Then 50 .mu.l LAL was added to each well. Plates were shaken
gently and incubated for 10 min at 37.degree. C. 100 .mu.l of
chromogenic substrate was added and incubated for 6 min at
37.degree. C. Finally, 50 .mu.l Stop Reagent was added and the
absorbance was measured at 405-410 nm on Spectramax M3 plate reader
(Molecular Device, Sunnyvale, Calif.).
As shown in TABLE 2, SnF2 and some other compounds inhibited LPS
activities in LAL assays
TABLE-US-00003 TABLE 2 Inhibition of LPS activities on LAL Assays
Inhibition of LAL activity % P. gingivalis LPS E. coli LPS 1690 1
ng/ml 1 ng/ml Samples 500 uM 50 uM 500 uM 50 uM Tin (II) fluoride
60 49 92 87 stannous chloride 48 21 89 65 Cetylpyridinium chloride
103 77 103 46 monohydrate Chlorhexidine 102 38 97 57 zinc citrate,
dihydrate 104 57 104 82 zinc lactate 58 0 66 0 potassium oxalate 8
0 1 6 Triclosan (irgasan) 0 0 10 0 1-Hydroxypyridine-2-thone 0 0 2
6 zinc salt sodium fluoride 0 0 4 5 Carboxymethyl cellulose 0 0 2 0
sodium
Example 4--Binding of BODIPY-TR-Cadaverine to LPS and Displacement
of LPS Binding by Stannous Fluoride
In addition to LAL quantification of LPS, the BODIPY method can be
utilized to assess the level of LPS. Detoxifying technologies are
able to target and neutralize bacterial virulence factors, such as
LPS and LTA. To develop such LPS and LTA sequestration
technologies, a high throughput screening was employed to identify
molecules that disrupt the activation of a Toll-like receptor by
LPS and LTA, and other virulence factors. The high throughput
screen utilizes the fluorescent dye BODIPY-TR-cadaverine
5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phe-
noxy)acetyl)amino)pentylamine hydrochloride (BC fluorescent dye),
purchased from Life Technologies (Carlsbad, Calif.), as described
previously by Wood, Miller and David (2004) (Comb Chem High
Throughput Screen 2004 May; 7(3):239-49. Anti-endotoxin agents. 1.
Development of a fluorescent probe displacement method optimized
for the rapid identification of lipopolysaccharide-binding
agents.). The experiment was carried out at 22.degree. C. E. coli
LPS (15 .mu.g/ml) was mixed in a well of a 96-well solid black flat
bottom plate (Corning Incorporated, Corning, N.Y.) with SNF2 and
cetylpyridinium chloride in 30 .mu.l of 50 mM Tris buffer at pH 7.4
for 10 mM, and then 20 .mu.l of 60 .mu.M BC fluorescent dye was
added right before fluorescence measurement at 22.degree. C., or
room temperature. Fluorescence measurements were performed in a
SpectraMax M3 automated 96 well plate reader (Molecular Device,
Sunnyvale, Calif.). The excitation wavelength was 580 nM and the
fluorescence emission was measured at 620 nM.
As shown in TABLE 3, leading anti-gingivitis technologies, such as
stannous fluoride, displaced LPS from BODIPY TR cadaverine.
TABLE-US-00004 TABLE 3 Displacement of LPS from binding to BODIPY
TR cadaverine Concentrations Displacement % mM Stannous fluoride
Cetylpyridinium chloride 0.16 2.45 9.98 0.31 2.79 31.11 0.63 12.69
68.05 1.25 49.44 91.12
Example 5--Cell Culture and Virulence Determination of
Lipopolysaccharide from Different Bacteria
Reporter gene cell lines, human HEK 293T cells, were purchased from
Invivogen of San Diego, Calif. The HEK 293T cells were stably
transfected with at least two exogenous genes, a TLR4 structural
gene, and a SEAP reporter gene, which is under the control of NFkB
transcriptional factors. The cell line is named here as TLR4-SEAP.
The reporter gene encodes a secreted enzyme, called embryonic
alkaline phosphatase or SEAP. The SEAP reporter is placed under the
control of the interferon-.beta. minimal promoter fused to five
NFkB and AP-1-binding sites. Furthermore, the TLR4-SEAP cell line
also contains a CD14 co-receptor gene, which is needed to transfer
LPS to TLR4 receptors. The recombinant TLR binds its ligand, or
distinct pathogen-associated molecule, initiates a chain of
responses, leading to recruitment of NFkB and AP1 transcription
factors to the reporter gene promoter, which induce expression of
SEAP.
Cell culture and treatment: 500,000 gene reporter cells were grown
and maintained in 15 ml growth medium, comprised of DMEM medium
supplemented with 10% fetal calf serum in T75 flasks for three days
at 37.degree. C., 5% CO.sub.2, and 95% humidity. For treatment,
wells of a 96-well plate were seeded with 10,000 cells/well in 100
.mu.L of growth medium. The cells were incubated for 72 hours at
37.degree. C., 5% CO.sub.2, and 95% humidity until day 4. On day 4,
medium was changed to assay medium (90 .mu.l), which is the DMEM
medium without fetal calf serum. LPS, bacteria and the culture
medium of bacterial growth, as described in EXAMPLE 1, were first
resolved or mixed with the assay medium. 10 .mu.l of the bacteria,
LPS and culture medium of bacterial growth were added to the
TLR4-SEAP cells. Samples were taken 24 hours later, following
addition of LPS, bacteria, and culture medium. Expression of the
reporter gene (SEAP) was quantified with a commercially available
kit (SEAP Reporter Gene Assay of Cayman Chemical Co., Ann Arbor,
Mich.).
EC50 was calculated using GraphPad Prism software (GraphPad
Software, La Jolla, Calif.). Samples with lower EC50 are more
potent in activating the TLR4 reporter gene than those with higher
EC50. As shown in FIG. 2A, LPS from E. coli has lower EC50 than P.
gingivalis, thus, was far more potent than P. gingivalis (Pg).
Salmonella Minnesota LPS is not as potent as that of E. coli, but
is far more potent than those of P. gingivalis LPS 1690 and 1435.
Each species of bacteria produces multiple forms of LPS. Each form
of LPS from the same species of bacteria has different potency in
stimulating TLR4-downstream signaling pathways. For example, Pg
1690 LPS is more potent than Pg1435/50. LPS is a component in
bacterial cell walls. Likely, E. coli cell wall is more virulent in
inducing production of proinflammatory cytokines in host cells than
P. gingivalis when they are in direct contact with host blood
cells. P. gingivalis had far higher EC50 than P. pallens and P.
nigrescens as shown in FIG. 2B in stimulating TLR4 reporter gene
expression, suggesting that P. pallens and P. nigrescens are more
likely to promote production of proinflammatory cytokines in host
cells than P. gingivalis.
Bacteria release LPS into the supernatant of bacterial culture. As
shown in FIG. 2C, the supernatant of P. pallens has an EC50 that is
similar to that of P. nigrescens, but far lower than that of P.
gingivalis, in stimulating expression of TLR4 reporter gene. Again,
those results imply that the products of P. pallens and P.
nigrescens are more likely to promote production of proinflammatory
cytokines in host cells than those of P. gingivalis.
Example 6--Development of Technology for Inhibition of LPS Effects
on Stimulating Expression of NFkB-Regulated Reporter Genes
Stannous fluoride is a leading anti-gingivitis technology in
P&G toothpaste products. Tests were conducted to understand
whether stannous fluoride could reduce LPS's ability to trigger
proinflammatory responses in host cells. TLR4-SEAP reporter cells
were prepared using the same conditions as described in EXAMPLE 5
in the presence or absence of LPS. Production of SEAP was
quantified also as described in EXAMPLE 5.
FIG. 3 shows the effect of stannous at various concentrations from
62.5 uM to 1,000 uM on 100 ng/ml E. coli LPS, as reported by
activation of TLR-4. At stannous concentrations of 500 uM or
higher, the level of E. coli induction of TLR-4 was decreased.
FIG. 4 shows the effects of stannous at various concentrations from
62.5 uM to 1,000 uM on P. gingivalis LPS, as reported by activation
of TLR-2. At stannous concentrations of 1000 uM, the level of P.
gingivalis induction of TLR-2 was decreased.
The data in FIG. 5 shows reduction of LPS activity by the stannous
ion, from a stannous fluoride salt. The data showed that stannous
fluoride, at 1.6 mM and 3.2 mM, reduce about 50% of P. gingivalis
LPS (500 ng/ml) activation on the TLR4 reporter system (One
asterisk means P<0.05, two asterisks mean P<0.01).
Example 7--Cell Culture and Virulence Determination of EC50 in
Activation of TLR4-SEAP Signal Transduction by Clinical Samples
The method described in EXAMPLE 5 is effective at determining the
potency of LPS from different bacteria. The same method was used to
determine the EC50 of clinical samples, as described in EXAMPLE 2.
As shown in FIG. 6, dental plaques from unhealthy sites had a
smaller EC50 than those from healthy sites, suggesting the dental
plaques from unhealthy sites contain more virulence factors.
The same method described in EXAMPLE 5 was used to examine the
clinical samples in another study. A clinical study was conducted
to evaluate sample collection methods and measurement procedures.
It was a controlled, examiner-blind study. Forty panelists met the
inclusion criteria, wherein in order to be included in the study,
each panelist must: Provide written informed consent to participate
in the study; Be 18 years of age or older; Agree not to participate
in any other oral/dental product studies during the course of this
study; Agree to delay any elective dentistry (including dental
prophylaxis) until the study has been completed; Agree to refrain
from any form of non-specified oral hygiene during the treatment
periods, including but not limited to the use of products such as
floss or whitening products; Agree to return for all scheduled
visits and follow study procedures; Must have at least 16 natural
teeth; Be in good general health, as determined by the
Investigator/designee based on a review of the health
history/update for participation in the study.
For Unhealthy Group (high bleeder group): Have at least 20 bleeding
sites (sites with a score of 1 or 2 on the GBI index); Have minimum
3 sampling sites with bleeding and pocket depth >3 mm but not
deeper than 4 mm; Have minimum 3 sampling sites without bleeding
and with pocket depth <2 mm
For Healthy Group (low bleeder group): Have maximum 3 bleeding
sites (sites with a score of 1 or 2 on the GBI index); No pockets
deeper than 2 mm. Twenty (20) panelists were qualified as
healthy--with up to 3 bleeding sites and with all pockets less than
or equal to 2 mm deep and twenty (20) panelists were qualified as
unhealthy--with greater than 20 bleeding sites with at least 3
pockets greater than or equal to 3 mm but not deeper than 4 mm with
bleeding, and at least 3 pockets less than or equal to 2 mm deep
with no bleeding for sampling. All panelists had up to 6 sites
identified as "sampling sites." The "sampling sites" had
supragingival and subgingival plaque collected at Baseline, Week 2
and Week 4. Subgingival plaque samples were taken from a gingival
sulcus from the pre-identified sites. Prior to sample collection,
the site had supragingival plaque removed with a curette. The site
was dried and subgingival plaque samples were collected with
another dental curette (e.g., Gracey 13/14, 15/16, 11/12, 7/8,
1/2.) Each Gracey curette is designed to adapt to a specific area
or tooth surface. For example, Gracey 13/14 is designed to adapt to
the distal surfaces of posterior teeth. Samples from each site were
placed in a pre-labeled 2.0 ml sterile tube containing 300 .mu.l of
DPBS buffer with about 50 of sterile 1 mm glass beads. Samples were
stored at 4.degree. C. The subgingival samples were stored at
-80.degree. C. until analyzed. The samples were thawed at room
temperature and dispersed in a TissueLyser II (Qiagen, Valencia,
Calif., USA) at 30 shakes per second for 3 min. Protein
concentrations of the dispersed subgingival samples were measured
using a Pierce microBCA Protein kit (ThermoFisher Scientific, Grand
Island, N.Y., USA) following the manufacturer's instruction.
Oral lavage samples were collected at wake up (one per panelist) by
rinsing with 4 ml of water for 30 seconds and then expectorating
the contents of the mouth into a centrifuge tube. These samples
were frozen at home until they were brought into the site in a cold
pack. Each panelist collected up to 15 samples throughout the
study. Saliva samples were frozen at -70.degree. C. from
submission.
All panelists were given investigational products: Crest.RTM.
Pro-Health Clinical Gum Protection Toothpaste (0.454% stannous
fluoride) and Oral-B.RTM. Indicator Soft Manual Toothbrush.
Panelists continued their regular oral hygiene routine, and did not
use any new products starting from the baseline to the end of four
week treatment study. During the four week treatment period,
panelists brushed their teeth twice daily, morning and evening, in
their customary manner using the assigned dentifrice and soft
manual toothbrush.
The subgingival plaques from the above clinical study were applied
to the TLR4 reporter cells in a procedure as described in EXAMPLE
5. FIG. 7A shows the results of a four-week study of 40 panelists
going from baseline out over four weeks of treatment with Crest
ProHealth Clinical toothpaste. The subgingival plaque samples in
bleeding sites on the high bleeders group stimulated high
expression of TLR4 reporter gene. More virulence in a sample
elicits higher RLU (relative luminescent units) readings in the
TLR4 reporter gene assay. As shown in FIG. 7A, the baseline samples
of the high bleeders group had higher RLU than those of the low
bleeders on both the bleeding and non-bleeding sites. After
treatment with Crest.RTM. Pro-Health Clinical Gum Protection
Toothpaste (0.454% stannous fluoride) and Oral-B.RTM. Indicator
Soft Manual Toothbrush for four weeks, the virulence was reduced at
week 4 in both high and lower bleeders groups at both bleeding and
non-bleeding sites.
The oral lavage samples were applied to the TLR4 reporter cells in
a procedure as described in EXAMPLE 5. As shown in FIG. 7B, oral
lavage (Healthy vs. Gingivitis) samples were evaluated in the
TLR4-SEAP reporter assay. The baseline samples of the high bleeders
group had higher RLU than those of the low bleeders. After
treatment with Crest.RTM. Pro-Health Clinical Gum Protection
Toothpaste (0.454% stannous fluoride) and Oral-B.RTM. Indicator
Soft Manual Toothbrush for four weeks, the virulence was reduced at
week 4 in the high bleeder group.
Example 8--Cell Culture and Virulence Determination of Lipoteichoic
Acids from Different Bacteria
The reporter gene cell lines, human HEK 293T cells, were purchased
from Invivogen of San Diego, Calif. The HEK 293T cells were stably
transfected with at least two exogenous genes, a TLR2 structural
gene, and SEAP reporter gene which is under the control of NFkB
transcriptional factors. The cell line is named here as TLR2-SEAP.
The reporter gene encodes a secreted enzyme, called embryonic
alkaline phosphatase or SEAP. The SEAP reporter is placed under the
control of the interferon-.beta. minimal promoter fused to five
NFkB and AP-1-binding sites. Furthermore, a CD14 co-receptor gene
was transfected into the reporter gene cells expressing TLR2, as
CD14 has been identified as a co-receptor for TLR2 ligands to
enhance the TLR response. The CD14 co-receptor is needed to
transfer LTA to TLR2 receptors. The recombinant TLR2 binds its
ligand, or distinct pathogen-associated molecule, initiates a chain
of responses, leading to recruitment of NFkB and AP1 transcription
factors to the reporter gene promoter, which induce expression of
SEAP.
Cell culture and treatment: 500,000 gene reporter cells were grown
and maintained in 15 ml growth medium, comprising DMEM medium
supplemented with 10% fetal calf serum in T75 flasks for three days
at 37.degree. C., 5% CO.sub.2, and 95% humidity. For treatment with
LTA, wells of a 96-well plate were seeded with 10,000 cells/well in
100 .mu.L of growth medium. The cells were incubated for 72 hours
at 37.degree. C., 5% CO.sub.2, and 95% humidity until day 4. On day
4, medium (100 .mu.L) was changed to DMEM medium without fetal calf
serum. LTA, LPS and bacterial cells, as described in EXAMPLE 7,
were added. Samples were taken 24 hours later, following addition
of samples. Expression of the reporter gene (SEAP) was quantified
with a commercially available kit (SEAP Reporter Gene Assay of
Cayman Chemical Co., Ann Arbor, Mich.).
As shown in FIGS. 8A, 8B, 8C and 8D, LTA, LPS, bacteria and the
supernatant of bacterial culture could bind to TLR2 and activate
TLR2 downstream signaling pathways in a dose-dependent manner. As
shown in FIG. 8A, B. subtilis (BS) LTA is more potent than that of
Enterococccus hirae. As shown in FIG. 8B, P. gingivalis LPS also
activated expression of the TLR2 reporter gene. For example,
Pg1690, as shown in FIG. 8B, activated TLR2-SEAP signal
transduction, and stimulated SEAP production. But as shown in FIG.
8B, E. coli LPS did not activate the TLR2-SEAP reporter cells. It
should also be noted that P. pallens, P. nigrescens and P.
gingivalis have similar EC50 in stimulating expression of TLR2
reporter gene (FIG. 8C). However, the released TLR2 ligands from
the three different bacteria have very different EC50 on activation
of TLR2 reporter gene (FIG. 8D).
Example 9--Cell Culture and Virulence Determination of EC50 in
Activation of TLR2-SEAP Signal Transduction by Clinical Samples
The method described in EXAMPLE 8 is effective in determining the
EC50 of LTA and other TLR2 ligands from different bacteria. The
same method was used to determine the EC50 of clinical samples, as
described in EXAMPLE 2. As shown in FIG. 9, dental plaques from
unhealthy (bleeding) sites had smaller EC50 than those from healthy
(non-bleeding) sites, suggesting the dental plaques from unhealthy
sites contain more virulence factors.
Clinical samples as described for FIG. 7A of EXAMPLE 7 were
examined using the TLR2-SEAP reporter gene assay. The results are
shown in FIG. 10A. The subgingival samples in unhealthy (bleeding)
sites from the unhealthy group (high bleeders) had more virulence
factors than other sites. The baseline samples of the high bleeders
group had higher RLU than those of the low bleeders on both the
bleeding and non-bleeding sites. After treatment with Crest.RTM.
Pro-Health Clinical Gum Protection Toothpaste (0.454% stannous
fluoride) and Oral-B.RTM. Indicator Soft Manual Toothbrush for four
weeks, the virulence was reduced at week 4 in both high and low
bleeders groups at both bleeding sites.
The clinical samples as described for FIG. 7B of EXAMPLE 7 were
examined using the TLR2-SEAP reporter gene assay. As shown in FIG.
10B, oral lavage (Healthy vs. Gingivitis) was evaluated. After
treatment with Crest.RTM. Pro-Health Clinical Gum Protection
Toothpaste (0.454% stannous fluoride) and Oral-B.RTM. Indicator
Soft Manual Toothbrush for four weeks, the virulence was reduced at
week 4 in the high bleeder group.
Example 10--Cell Culture and Virulence Determination of Flagellins
from Different Bacteria
The reporter gene cell lines, human HEK 293T cells, were purchased
from Invivogen of San Diego Calif. The HEK 293T cells were stably
transfected with two exogenous genes, a TLR5 structural gene, and
SEAP reporter gene which is under the control of NFkB
transcriptional factors. The cell line was named as TLR5-NFkB-SEAP.
The reporter gene encodes a secreted enzyme, called embryonic
alkaline phosphatase or SEAP. The SEAP reporter is placed under the
control of the interferon-.beta. minimal promoter fused to five
NFkB and AP-1-binding sites. The recombinant TLR5 binds to its
ligand, or distinct pathogen-associated molecule, and initiates a
chain of responses leading to recruitment of NFkB and AP1
transcription factors to the reporter gene promoter, which induce
expression of SEAP.
Cell culture and treatment: 500,000 gene reporter cells were grown
and maintained in DMEM medium supplemented with 10% fetal calf
serum in T75 flasks for three days at 37.degree. C., 5% CO.sub.2,
and 95% humidity. For treatment with flagellin, wells of a 96-well
plate were seeded with 10,000 cells/well in 100 .mu.L of growth
medium. The cells were incubated for 72 hours at 37.degree. C., 5%
CO.sub.2, 95% humidity until day 4 after cells were seeded onto
wells of a 96-well plate. On day 4, medium (100 .mu.L) was changed
to DMEM medium without fetal calf serum. S. subtilis and S. aureus
flagellin were added at a range of concentration from 0.97 ng to 1
.mu.g/ml. Samples were taken at 6 and 24 hours later after adding
flagellin. Expression of reporter gene (SEAP) was quantified with a
commercially available kit (SEAP Reporter Gene Assay of Cayman
Chemical Co., Ann Arbor, Mich.).
FIG. 11 shows both flagellins (B. subtilis and P. aeruginosa) could
activate TLR5 downstream signaling pathways. Flagellin from B.
subtilis stimulated TLR5-SEAP signaling transduction in a
dose-dependent manner. The EC50 of flagellin on TLR5 was 0.02 ng/ml
at 5 hours and 0.014 ng/ml at 23 hours. The EC50 of flagellin from
Pseudomonas aeruginosa on TLR5 was 0.0049 at 5 hours and 0.0019 at
23 hours. Flagellin from P. aeruginosa was more potent on
stimulating TLR5 signaling pathways.
Example 11--Cell Culture and Virulence Determination of LPS from
Different Bacteria in THP1 Dual Reporter Cells
Bacterial cell wall and membrane components are recognized by TLR2.
TLR2 recognizes the microbial motifs PGN
(peptidoglycan)/lipoproteins/dectin and LPS. TLR1 and TLR6 form
heterodimers with TLR2 and bind to triacylated lipoproteins and
diacylated lipoproteins, respectively. THP1 NFkB-SEAP and
IRF-Lucia.TM. Reporter Monocytes were purchased from Invivogen, San
Diego, Calif. THP1-Dual cells were derived from the human THP-1
monocyte cell line by stable integration of two inducible reporter
constructs. THP1-Dual cells feature the Lucia gene under the
control of an ISG54 (interferon-stimulated gene) minimal promoter
in conjunction with five interferon-stimulated response elements.
THP1-Dual cells also express a SEAP reporter gene driven by an
IFN-b minimal promoter fused to five copies of the NF-kB consensus
transcriptional response element and three copies of the c-Rel
binding site. As a result, THP1-Dual cells allow the simultaneous
study of the NFkB pathway, by monitoring the activity of SEAP, and
the interferon regulatory factor (IRF) pathway, by assessing the
activity of Lucia (IRF-Luc). Both reporter proteins are readily
measurable in the cell culture supernatant. This THP-1 cell line
possesses functional TLR1, TLR2, TLR4, TLR5, TLR6 and TLR8,
purchased from Invivogen. TLR4 senses LPS from Gram-negative
bacteria while TLR5 recognizes bacterial flagellin from both
Gram-positive and Gram-negative bacteria, TLR8 detects long
single-stranded RNA.
Culture and treatment: The THP1-dual cells were cultured in 15 ml
growth medium (RPMI 1640 with 10% heat-inactivated fetal bovine
serum) in a T75 flask at 37.degree. C. and 5% CO.sub.2. Cells were
passed every 3 to 4 days by inoculating 300,000-500,000 cells/ml
into a fresh T75 flask with 15 ml of fresh growth medium. To
determine the effect of bacterial components on reporter gene
expression, wells in 96-well plates were seeded at 100,000 cells in
90 .mu.l of growth medium. 10 .mu.l of bacterial wall and membrane
components, or heat-killed whole bacteria, were added to each well.
After incubation for 18 hours at 37.degree. C. and 5% CO.sub.2,
secreted luciferase and SEAP were quantified with commercially
available assay kits (QUANTI-Luc of Invivogen, San Diego, Calif.
for luciferase; SEAP Reporter Gene Assay of Cayman Chemical Co.,
Ann Arbor, Mich. for SEAP).
DHP1-dual reporter cells were treated with three different
preparations of LPS as shown in FIG. 12A. All three LPS (ng/ml)
activated production of NFkB-SEAP reporter genes in a
dose-dependent manner. In addition, Pg 1690 LPS and E. coli LPS
also stimulated expression of the IRF-luciferase reporter gene.
TLR4 ligands, upon binding to TLR4 receptors, activate at least two
signaling pathways. One is a common pathway NFkB-SEAP, which can be
activated by all TLR ligands upon binding to their specific
receptors. For example, TLR2 ligand, LTA, can bind to TLR2
receptors and activate the NFkB-SEAP signaling pathway. Similarly,
TLR4 ligand, LPS, upon binding to TLR4 receptors, also is able to
activate the NFkB-SEAP signaling transduction. As shown in FIG.
12A, E. coli LPS is a more potent ligand than P. gingivalis 1690
LPS on activation of both NFkB-SEAP and IRF-luciferase signaling
transduction. THP-1 cells produce several functional TLR receptors.
And all TLR receptors can activate the NFkB pathway, thus promoting
expression of the NFkB-SEAP reporter gene. The reading of NFkB-SEAP
is the collective actions of all TLR receptors, such as TLR2, TLR1,
TLR6 and TLR4. All LPS from different bacteria stimulated NFkB-SEAP
reporter gene. IRF-luciferase reporter gene, on the other hand, is
driven by a limited number of TLR receptors, primarily TLR3, TLR4,
TLR7, TLR8 and TLR9. Both P. gingivalis LPS 1690 and E. coli LPS
stimulated expression of IRF-luciferase in a dose-dependent
fashion.
The THP-1 reporter cells were used to examine the clinical samples
as described for FIG. 7B of EXAMPLE 7. As shown in FIG. 12B, oral
lavage (Healthy vs. Gingivitis) was evaluated using the IRF-Luc
reporter gene in THP-1 cells. After treatment with Crest.RTM.
Pro-Health Clinical Gum Protection Toothpaste (0.454% stannous
fluoride) and Oral-B.RTM. Indicator Soft Manual Toothbrush for four
weeks, the virulence was reduced at week 4 in both high and lower
bleeders groups.
The THP-1 reporter cells were used to examine the clinical samples
as described for FIG. 7A of EXAMPLE 7. As shown in FIG. 12C, the
subgingival Plaque (Healthy vs. Gingivitis) was examined using the
NFkB reporter gene in THP-1 cells. The baseline samples of the high
bleeders group had higher RLU than those of the low bleeders. After
treatment with Crest.RTM. Pro-Health Clinical Gum Protection
Toothpaste (0.454% stannous fluoride) and Oral-B.RTM. Indicator
Soft Manual Toothbrush for four weeks, the virulence was reduced at
week 4 in the bleeding sites in both high and lower bleeders
groups.
Example 12--Cell Culture and Virulence Determination of LTA from
Different Bacteria and Biofilms in THP1 Dual Reporter Cells
THP1 dual reporter cells also express TLR2, TLR1 and TLR6
receptors. Bacterial cell wall and some membrane components are
recognized by TLR2, TLR1 and TLR6. TLR2 recognizes the microbial
motifs PGN (peptidoglycan)/lipoproteins/dectin and LPS. To
determine whether LTA from different bacteria have different
effects on stimulating NFkB-SEAP reporter gene expression in the
THP1 dual reporter cells, the cells were prepared and treated in
the same procedures as described in EXAMPLE 11. As shown in FIG.
13, LTA from both B. subtilis and S. aureus had similar potency in
promoting reporter gene expression in the THP1 dual reporter
cells.
Example 13--Distinguishing Bacterial Components from Different
Bacteria in Human Primary Gingival Epithelial Cells
Primary human gingival epithelial cells were purchased from Zen-bio
(Research Triangle Park, N.C.), and maintained in 15 ml of growth
medium (CellnTec medium supplemented with CellnTec Growth
Supplement, purchased from CellnTec Advanced Cell Systems AG, Bern,
Switzerland) in T75 flasks at 37.degree. C. under a 5% CO2
atmosphere. As the experiment was done at 24 h, 48 h and 72 h time
point and with assay media, CellnTec medium alone or with
supplements, six 96 well plates were seeded with 7,500 cells/well
in 100 .mu.l of CELLnTEC growth medium at 37.degree. C. under a 5%
CO2 atmosphere. The growth medium was changed to assay medium right
before adding LPS or bacterial DNA. For example, if the assay
medium was CellnTec medium without supplements, 100 .mu.l of
CellnTec medium was added without supplements in each well. If the
assay medium was the growth medium, 100 .mu.l of growth medium was
added to each well. The P. gingivalis LPS and bacterial DNA were
added to the cells. At 24 h, 48 h and 72 h, medium was collected
for analysis. Cytokines were measured using Elisa kits from Meso
Scale Discovery (Rockville, Md.), as per the manufacturer's
instructions.
As shown in TABLE 4, human primary gingival epithelial cells were
treated with P. gingivalis DNA at 0, 0.3, 1 and 2 .mu.g/ml. The
cultures were harvested at 24 and 48 hours after treatment and six
proinflammatory cytokines (interferon-.gamma., IL-1.beta., IL-2,
IL-10, IL-12p70 and TNF-.alpha.) were analyzed using ELISA kits
from Meso Scale Discovery. As shown in TABLE 4, expression of
interferon-.gamma., IL-1.beta., IL-2, IL-10, IL-12p70 and
TNF-.alpha. was low, or almost undetectable (each value is the mean
of three replicate in one experiment). They were not viable
biomarkers in distinguishing bacterial DNA. The results in TABLE 4
illustrate the lack of inflammatory response from human gingival
epithelial cells, thus demonstrating the need to use an engineered
cell.
TABLE-US-00005 TABLE 4 Screening of Human Gingival Epithelial Cells
for Inflammatory Markers treated with P. gingivalis DNA Production
of cytokines (pg/ml) in primary human gingival epithelial cells
treated with P. gingivalis genomic DNA P. P. gingivalis gingivalis
genomic 24 48 genomic 24 48 DNA hours hours DNA hours hours
Interferon 0 ug 0 0.25 IL-1 0 ug 0 0.5 gamma 0.3 ug 0 0.33 beta 0.3
ug 0 0.33 1 ug 0 0 1 ug 0 0 2 ug 0.33 0.67 2 ug 0 0 IL-10 PG DNA
0.5 1 IL- PG DNA 0 0.25 0 ug 12p70 0 ug PG DNA 0.67 0.33 PG DNA
0.67 0 0.3 ug 0.3 ug PG DNA 0 0 PG DNA 0 0.67 1 ug 1 ug PG DNA 0.33
0.33 PG DNA 0 0.33 2 ug 2 ug IL-2 PG DNA 0.5 1 TNF- PG DNA 1 1.5 0
ug alpha 0 ug PG DNA 0 0.67 PG DNA 1.67 1.33 0.3 ug 0.3 ug PG DNA
0.33 1 PG DNA 0.67 1 1 ug 1 ug PG DNA 0.33 0.67 PG DNA 1.33 1.33 2
ug 2 ug
Human primary gingival epithelial cells were treated with P.
gingivalis LPS at 0, 0.3, 1 and 2 .mu.g/ml in the procedures
described above. As shown in TABLE 5, again, expression of
interferon-.gamma., IL-1.beta., IL-2, IL-10, IL-12p70 and
TNF-.alpha. was low, or almost undetectable. They were not viable
biomarkers in distinguishing bacterial LPS in primary human
gingival epithelial cells. The results in TABLE 5 further
illustrate how human gingival cells were not sufficiently sensitive
to bacterial virulence factors for an assay, and thus the need to
utilize a cell line capable of demonstrating a dose dependent
response to virulence factors.
TABLE-US-00006 TABLE 5 Screening of Human Gingival Epithelial Cells
for Inflammatory Markers treated with P. gingivalis LPS Production
of cytokines (pg/ml) in primary human gingival epithelial cells
treated with P. gingivalis LPS 24 h 48 h 24 h 48 h Interferon PG
lPS 0 ug 0.00 0.25 IL-1 PG lPS 0 ug 0.00 0.50 gamma PG LPS 0.3 ug
0.00 0.00 beta PG LPS 0.3 ug 0.00 0.67 PG LPS 1 ug 0.33 0.33 PG LPS
1 ug 0.00 0.00 PG LPS 2 ug 0.00 0.00 PG LPS 2 ug 0.00 1.00 IL-10 PG
lPS 0 ug 0.50 1.00 IL- PG lPS 0 ug 0.00 0.25 PG LPS 0.3 ug 0.67
0.67 12p70 PG LPS 0.3 ug 0.00 0.00 PG LPS 1 ug 0.00 0.67 PG LPS 1
ug 0.00 0.33 PG LPS 2 ug 0.33 0.67 PG LPS 2 ug 0.67 0.00 IL-2 PG
lPS 0 ug 0.50 1.00 TNF- PG lPS 0 ug 1.00 1.50 PG LPS 0.3 ug 0.33
0.67 alpha PG LPS 0.3 ug 1.33 0.67 PG LPS 1 ug 0.33 1.00 PG LPS 1
ug 2.00 1.33 PG LPS 2 ug 1.33 1.00 PG LPS 2 ug 0.67 1.33
Example 14--Gingivitis-Enriched Bacteria Reduced in Abundance in
Six Weeks of Gingivitis Treatment
A randomized, two-group clinical study was conducted with 69
panelists (35 in the negative control group and 34 in the test
regimen group). Panelists were 39 years old on average, ranging
from 20 to 69, and 46% of the panelists were female. Treatment
groups were well balanced, since there were no statistically
significant (p.gtoreq.0.395) differences for demographic
characteristics (age, ethnicity, gender) or starting measurements
for Gingival Bleeding Index (GBI); mean=29.957 with at least 20
bleeding sites, and Modified Gingival Index (MGI); mean=2.086. All
sixty-nine panelists attended each visit and completed the
treatment process. The following treatment groups were compared
over a 6-week period:
Test regimen: Crest.RTM. Pro-Health Clinical Plaque Control (0.454%
stannous fluoride) dentifrice, Oral-B.RTM. Professional Care 1000
with Precision Clean brush head and Crest.RTM. Pro-Health
Refreshing Clean Mint (0.07% CPC) mouth rinse. Control regimen:
Crest.RTM. Cavity Protection (0.243% sodium fluoride) dentifrice
and Oral-B.RTM. Indicator Soft Manual toothbrush.
Dental plaques were collected from the same panelists in the test
regimen in the clinical study as described in EXAMPLE 2. A
supragingival sample was taken from each panelist with a sterile
curette at the tooth/gum interface, using care to avoid contact
with the oral soft tissue. Plaques were sampled from all available
natural teeth (upper arch only) until no plaque was visible.
Following sampling, the plaque samples were placed into a
pre-labeled (panelist ID, sample initials, visit, and date)
Eppendorf tube with 1 ml of PBS/Glycerol buffer and about 50 of
sterile 1 mm glass beads, stored on ice until all samples were
collected. The samples were then transferred to a -70.degree. C.
freezer for storage until further processing. Genomic DNA was
isolated from supragingival plaque samples using QIAamp.RTM.
genomic DNA kits (Qiagen, Germany) following manufacturer's
instruction. Metasequencing was carried out at BGI Americas
Corporation (Cambridge, Mass.). All data were analyzed at Global
Biotech of Procter & Gamble Company in Mason, Ohio.
Clinical measurements: Bleeding sites (GBI) were decreased in the
test regimen significantly on week 1, 3 and 6 in comparison to the
control regimen (FIG. 14). Similarly, Inflammation (MGI) grades
also decreased in the test regimen (FIG. 14).
Genomic DNA of the supragingival plaques in the test regimen was
sequenced. As shown in FIG. 15, abundance of certain bacteria in
the supragingival plaques changed in the six week treatments.
Certain bacteria, such as Porphyromonas sp oral taxon 279 and
Prevotella pallens, were decreased in weeks 1 and 3 (FIG. 15). The
amount of each bacterial species was plotted over the four time
periods of the treatment. The amount of certain bacteria, such as
Peptostreptococcus stomatis and Prevotella intermedia, was reduced
during the six week of treatment as shown in FIG. 15. This is also
shown in FIG. 16A-1, FIG. 16A-2, and FIG. 16A-3.
Example 15--Production of Cytokines, Chemokines and Other Bioactive
Proteins Decreased as Gingivitis Symptoms were Alleviated During 6
Week of Treatment
In the same clinical study as described in EXAMPLE 14,
gingival-brush samples were collected from the same panelists as in
EXAMPLE 14. Before sampling, panelists rinsed their mouths for 30
seconds with water. A dental hygienist then sampled the area just
above the gumline using a buccal swab brush (Epicentre
Biotechnologies cat.# MB100SP). The swab was immediately placed
into 1 ml extraction buffer [PBS, 0.25M NaCl, 1.times. Halt.TM.
Protease Inhibitor Single-Use Cocktail (Lifetechnologies, Grand
Island, N.Y.)] in a 1.5 ml Eppendorf tube vortexed for 30 seconds,
and immediately frozen on dry ice and stored in a -80 C freezer
until analysis. The samples were taken out of freezer, thawed and
extracted by placing the samples on a tube shaker for 30 minutes at
4.degree. C. The tubes were centrifuged at 15000 RPM for 10 min in
Eppendorf Centrifuge 5417R (Eppendorf, Ontario, Canada) to pellet
any debris. The extract (800 .mu.l) was analyzed for protein
concentrations using the Bio-Rad protein assay (BioRad, Hercules,
Calif.).
Forty proteins were measured in the gingival samples using V-PLEX
Human Biomarker 40-Plex Kit (Meso Scale Diagnostics Rockville,
Md.). The assay was performed following the manufacturer's
instruction.
Among the proteins measured in the gingival samples, most proteins
in the Proinflammatory Panel 1 (human), Cytokine Panel 1 (human),
Chemokine Panel 1 (human), Angiogenesis Panel 1 (human), and
Vascular Injury Panel 2 (human) had significant changes in their
abundance during the 6-week treatment (TABLE 6). Those include
FN-.gamma., IL-1.beta., IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70,
IL-13, TNF-.alpha., GM-CSF, IL-5, IL-16, IL-7, IL-12/IL-23p40,
IL-1.alpha., VEGF-A, IL-17A, IL-15, TNF-.beta., IL-8 (HA), MCP-1,
MCP-4, Eotaxin, IP-10, MDC, Eotaxin-3, TARC, MIP-1.alpha.,
MIP-1.beta., VEGF-C, VEGF-D, Tie-2, Flt-1/VEGFR1, PlGF, FGF
(basic), SAA, CRP, VCAM-1, and ICAM-1.
TABLE-US-00007 TABLE 6 Changes in abundance of proteins in the
gingival-brush samples Mean .alpha. = 0.05 Baseline Week 1 Week 3
Week 6 Baseline Week 1 Week 3 Week 6 ICAM-1 16.035 12.209 10.090
9.767 A B B, C C IL-1.alpha. 3.554 2.331 2.181 1.891 A A, B B, C C
IL-1.beta. 53.666 35.575 24.295 24.440 A B C C TNF-.beta. 0.0013
0.0010 0.0008 0.0007 A B C C IL-12p70 0.172 0.148 0.118 0.127 A A,
B C B, C IL-13 0.805 0.762 0.624 0.648 A A, B C B, C IL-4 0.127
0.115 0.090 0.096 A A, B C B, C IL-5 0.004 0.003 0.002 0.003 A B C
B, C CRP 15.637 12.743 12.385 5.809 A A A B Eotaxin 0.077 0.064
0.059 0.059 A A, B B B GM-CSF 0.010 0.008 0.008 0.008 A B B B IFN
0.530 0.446 0.378 0.386 A A, B B B IL-10 0.875 0.490 0.423 0.244 A
A, B B B IL-15 0.005 0.003 0.003 0.003 A B B B IL-16 0.466 0.345
0.342 0.295 A B B B IL-6 0.196 0.192 0.168 0.150 A A A, B B IL-7
0.004 0.003 0.003 0.003 A B B B IL-8 856.276 652.066 567.361
572.602 A B B B MCP-1 0.053 0.047 0.039 0.039 A A, B B B MDC 0.399
0.407 0.345 0.339 A A B B Mean .alpha. = 0.05 Baseline Week 1 Week
3 Week 6 Baseline Week 1 Week 3 Week 6 SAA 7.039 6.905 6.092 5.162
A A A, B B Tie-2 0.273 0.239 0.267 0.221 A A, B A B VCAM-1 4.971
3.706 3.156 2.892 A B B B VEGF 0.625 0.511 0.478 0.480 A B B B VEGF
2 0.772 0.661 0.620 0.582 A B B B VEGF-D 0.057 0.052 0.051 0.045 A
A, B A, B B VEGF-C 0.145 0.149 0.125 0.137 A, B A B A, B TARC 0.020
0.029 0.019 0.019 A B A A bFGF 0.020 0.015 0.012 0.013 A A A A
Eotaxin-3 0.095 0.108 0.091 0.094 A A A A Flt-1 0.390 0.518 0.433
0.415 A B A, B A IL-12p40 0.039 0.031 0.028 0.031 A A A A IL-2
0.166 0.199 0.210 0.162 A A A A IL-8 (HA) 47.508 44.362 41.260
39.119 A A A A IP-10 0.540 1.688 0.740 0.606 A A A A MCP-4 0.023
0.023 0.020 0.022 A A A A MIP-1.alpha. 0.091 0.091 0.084 0.080 A A
A A MIP-1.beta. 0.091 0.100 0.110 0.094 A A A A TNF.alpha. 2.009
2.067 2.021 1.670 A A A A
Example 16--One Hundred Seventy Metabolites were Identified in
Gingival Samples
The same gingival-brush samples as described in EXAMPLE 15 were
used for metabonomic analyses. Fourteen panelists were selected
randomly from each treatment group to determine if any metabolite
concentrations were changed in gingival samples during the first 3
weeks of treatment. Both baseline and week 3 samples were sent to
Metabolon, Inc. (Durham, N.C.) for metabonomic measurement. 170
metabolites were identified and quantified. As shown in TABLE 7,
some metabolite concentrations were changed during the first 3
weeks of treatment. Citrulline concentrations in the gingival
samples were reduced after three weeks of treatment in the
treatment regimen group. Similarly, ornithine was also reduced in
the treatment regimen group after three weeks of treatment.
Reduction of citrulline and ornithine was likely associated with
alleviation of gingivitis.
TABLE-US-00008 TABLE 7 Comparison of metabolites in gingival brush
samples between baseline and week 3 during gingivitis treatment
Baseline 3 week 3 week/ Biochemical Name mean mean baseline p-value
q-value Mass 13-HODE + 9-HODE 1.0877 0.7088 0.65 0.0601 0.1338
295.2 1- 1.2294 0.8274 0.67 0.038 0.1035 500.3
arachidonoylglycerophosphoethanolamine 1- 0.7378 1.0747 1.46 0.0767
0.1548 478.3 oleoylglycerophosphoethanolamine
2-methylbutyrylcarnitine 1.7769 0.6997 0.39 0.0034 0.0546 246.1
(C5) adenosine 5'- 1.4092 0.8451 0.6 0.0295 0.0956 348.1
monophosphate (AMP) alanine 0.8721 1.102 1.26 0.0318 0.0973 115.9
arginylleucine 1.4447 0.6819 0.47 0.0084 0.0777 288.3
arginylphenylalanine 0.9616 0.3335 0.35 0.0119 0.0777 322.2
asparagylleucine 0.9295 0.6122 0.66 0.0698 0.1465 246.2 citrulline
1.0147 0.71 0.7 0.0104 0.0777 176.1 deoxycarnitine 3.2381 0.6088
0.19 0.0003 0.0168 146.1 EDTA 1.5985 0.8384 0.52 0.0138 0.0777
291.1 erythritol 1.625 0.8085 0.5 0.0582 0.1325 217 fructose 1.9933
1.1106 0.56 0.0847 0.1605 217 glutamine 1.2459 0.8366 0.67 0.0374
0.1035 147.2 glutathione, oxidized 1.0161 1.4669 1.44 0.087 0.1605
613.1 (GSSG) glycerol 1.3783 0.8308 0.6 0.0391 0.1035 205 lauryl
sulfate 1.685 0.8623 0.51 0.0397 0.1035 265.2 leucine 1.2158 0.9359
0.77 0.0613 0.1338 132.2 leucylleucine 0.9505 0.4393 0.46 0.0251
0.0877 245.1 lysylleucine 1.2009 0.5275 0.44 0.0036 0.0546 260.2
lysylphenylalanine 1.1682 0.4563 0.39 0.0095 0.0777 294.3 maltose
0.8727 1.4481 1.66 0.022 0.0877 204.1 maltotriose 1.0456 1.8347
1.75 0.0858 0.1605 204 mannitol 1.3004 0.7982 0.61 0.042 0.107
319.1 ornithine 1.2916 0.7069 0.55 0.0367 0.1035 141.9 palatinitol
1.4395 0.8272 0.57 0.0782 0.1549 204 phosphate 1.4008 0.8376 0.6
0.0208 0.0877 298.9 proline 1.405 0.99 0.7 0.0033 0.0546 116.1
propionylcarnitine 1.2565 0.7688 0.61 0.0201 0.0877 218.2
pyroglutamine 1.3424 0.7873 0.59 0.0136 0.0777 129.2
serylisoleucine 1.1753 0.7169 0.61 0.0814 0.1583 219.2 spermidine
1.1613 0.8678 0.75 0.0687 0.1465 146.2 succinate 1.2929 0.8113 0.63
0.0754 0.1548 247 threonylleucine 1.1513 0.4931 0.43 0.0044 0.0594
231.2 threonylphenylalanine 1.7693 0.918 0.52 0.0233 0.0877 267.2
trehalose 2.3563 0.9084 0.39 0.0054 0.0647 361.2 tryptophan 1.1518
0.9089 0.79 0.0487 0.1185 205.1 tyrosine 1.383 1.0299 0.74 0.0161
0.0787 182.1 valine 1.1598 0.9271 0.8 0.0304 0.0956 118.1
valylvaline 0.9347 0.8231 0.88 0.0508 0.1207 215.2 X-13671 0.5035
0.918 1.82 0.0545 0.1267 315.3 X-14588 1.3647 0.8378 0.61 0.024
0.0877 151 X-16103 1.3643 0.8461 0.62 0.0297 0.0956 99.3 X-17266
1.3158 0.576 0.44 0.0003 0.0168 530.4 X-17375 1.4785 0.8387 0.57
0.0189 0.0877 357.1 X-18472 0.6138 1.1441 1.86 0.0011 0.0405 827.1
X-18779 1.3756 0.8035 0.58 0.0162 0.0787 209.1 X-19607 1.5237
0.7167 0.47 0.002 0.0537 366.1 X-19609 1.3284 0.7721 0.58 0.016
0.0787 204 X-19612 1.3896 0.7843 0.56 0.01 0.0777 427.2 X-19613
1.3412 0.7535 0.56 0.0099 0.0777 429.3 X-19614 1.3378 0.7343 0.55
0.0454 0.113 570.1 X-19807 1.3478 0.8411 0.62 0.0244 0.0877 93
X-19808 1.3348 0.8368 0.63 0.0254 0.0877 95 X-19850 1.3576 0.7519
0.55 0.011 0.0777 334.2 X-19857 1.3357 0.8032 0.6 0.038 0.1035 230
X-20000 1.2784 0.7536 0.59 0.0133 0.0777 81.2
Example 17--Citrulline was Reduced in Regimen Treatment Over 6
Weeks
Quantitation of citrulline and ornithine from the extracts of the
Gingival-brush samples was conducted using gradient hydrophilic
interaction liquid chromatography with tandem mass spectrometry
(HILIC/MS/MS). Gingival-brush samples were obtained from the same
human panelists in the clinical study as described in EXAMPLE 14,
and were placed into extraction buffer as described in EXAMPLE 15.
The supernatants were subject to both HILIC/MS/MS and BCA analysis.
For free citrulline and ornithine analysis, the extracts of the
Gingival-brush samples were analyzed either directly (50 .mu.l
undiluted sample solution) in 50/50 acetonitrile/ultra-pure water
with 0.754% formic acid or diluted fivefold. For total citrulline
and ornithine analysis, the extracts of the Gingival-brush samples
were first hydrolyzed using 6 N HCl (50 .mu.L of extract with 450
.mu.L of 6N HCl), no shaking, and placed on a hot plate at
110.degree. C. for 16 hours. The hydrolyzed samples were then dried
down under vacuum at room temperature (Savant speedvac of
Lifetechnology, Grand Island, N.Y.) and then reconstituted in 1 ml
of dilution solution (50/50 acetonitrile/ultra-pure water with
0.754% formic acid) for analysis. The standards and the samples
were analyzed using gradient hydrophilic interaction liquid
chromatography with tandem mass spectrometry (HILIC/MS/MS).
Analytes and the corresponding ISTDs (stable isotope labeled
internal standard) were monitored by electrospray ionization (ESI)
in positive mode using the selected-reaction-monitoring schemes
shown in TABLE 8. A standard curve was constructed by plotting the
signal, defined here as the peak area ratio (peak area analyte/peak
area ISTD), for each standard versus the mass of each analyte for
the corresponding standard. The mass of each analyte in the
calibration standards and Gingival-brush extract samples were then
back-calculated using the generated regression equation. The
concentration of protein bound citrulline or ornithine was
calculated as the result of subtracting the concentration of free
citrulline or ornithine from the concentration of total citrulline
or ornithine, respectively. The result was reported as the
concentration of citrulline or ornithine or the result was
standardized by dividing by the amount of citrulline or ornithine
by the amount of the total proteins that were found in the
extract.
TABLE-US-00009 TABLE 8 Multiple Reaction Monitoring (MRM)
transitions for analytes and their corresponding stable isotope
labeled internal standards Analytes MRM Internal Standards MRM
Citrulline 176 .fwdarw. 159 d.sub.7-Citrulline 181 .fwdarw. 164
Ornithine 133 .fwdarw. 70 d.sub.6-Ornithine 139 .fwdarw. 76
All samples from all panelists of the Test regimen [Crest.RTM.
Pro-Health Clinical Plaque Control (0.454% stannous fluoride)
dentifrice, Oral-B.RTM. Professional Care 1000 with Precision Clean
brush head and Crest.RTM. Pro-Health Refreshing Clean Mint (0.07%
CPC) mouth rinse] were analyzed. As shown in FIG. 16, citrulline
levels reduced rapidly in the first week of treatment, and then
continued to decline gradually in weeks 3 and 6 of treatment. These
results are consistent with clinical observations, where gingival
bleeding sites (GBI) and the gingival inflammation (MGI) were
reduced over the 6-week treatment period.
Example 18--Levels of Proteins Containing Ornithine Decreased Over
6 Week Treatment
The same samples as described in EXAMPLE 17 were analyzed using
procedures as described in EXAMPLE 17. Gingivitis was treated for 6
weeks. Baseline (BL) represents diseased status. Symptoms of
gingivitis were alleviated from week 1 to week 6 treatments.
Protein bound ornithine (the difference between total and the free
ornithine) was higher in gingivitis as shown in FIG. 17. Protein
bound ornithine was reduced gradually as gingivitis was decreased
in severity.
Example 19--Expression of Enzymes in the
Ornithine-Citrulline-Arginine Cycle was Changed in Gingival Samples
During the 6 Week Treatment
Gingival samples were collected as described in EXAMPLES 15, from
the same panelists as in EXAMPLE 15, and were used to examine the
expression of genes during 6 weeks of treatments with Test regimen
[Crest.RTM. Pro-Health Clinical Plaque Control (0.454% stannous
fluoride) dentifrice, Oral-B.RTM. Professional Care 1000 with
Precision Clean brush head and Crest.RTM. Pro-Health Refreshing
Clean Mint (0.07% CPC) mouth rinse] and Control regimen [Crest.RTM.
Cavity Protection (0.243% sodium fluoride) dentifrice and
Oral-B.RTM. Indicator Soft Manual toothbrush].
After harvesting the samples, the brush was completely immersed in
the RNAlater solution (1 ml in a 1.5 ml Eppendorf tube) for keeping
RNA from degrading during transport and storage (Qiagen, Valencia,
Calif.). The microcentrifuge tubes were vortexed/mixed for 30
seconds, immediately frozen on dry ice, stored and transferred on
dry ice to the lab for biomarker analysis. RNA isolation and
microarray analysis were performed as described previously in a
publication (Offenbacher S, Barros S P, Paquette D W, Winston J L,
Biesbrock A R, Thomason R G, Gibb R D, Fulmer A W, Tiesman J P,
Juhlin K D, Wang S L, Reichling T D, Chen K S, Ho B. J Periodontol.
2009 December; 80(12):1963-82. doi: 10.1902/jop.2009.080645.
Gingival transcriptome patterns during induction and resolution of
experimental gingivitis in humans).
The ornithine-citrulline-arginine cycle consists of four enzymes
(FIG. 18). The main feature of the cycle is that three amino acids
(arginine, ornithine, and citrulline) can be converted to each
other. The first enzyme is ornithine transcarbamoylase, which
transfers a carbamoyl group from carbamoyl phosphate to ornithine
to generate citrulline. This reaction occurs in the matrix of the
mitochondria. Expression of ornithine transcarbamoylase was reduced
in the treatment (FIG. 19). The second enzyme is argininosuccinate
synthetase. This enzyme uses ATP to activate citrulline by forming
a citrullyl-AMP intermediate, which is attacked by the amino group
of an aspartate residue to generate argininosuccinate. This and
subsequent two reactions occur in the cytosol. Again, expression of
argininosuccinate synthetase decreased during the treatment. The
third enzyme is argininosuccinate lyase, which catalyzes cleavage
of argininosuccinate into fumarate and arginine. The last enzyme is
argininase. Argininases cleave arginine to produce urea and
ornithine. In a contrast to the decreased expression of ornithine
transcarbamoylase and argininosuccinate synthetase genes,
argininase I and II increased (FIG. 19).
Arginine is also a substrate for nitric oxide synthase, which
oxidizes arginine to produce citrulline and nitric oxide.
Expression of nitric oxide synthase gene increased too (FIG.
19).
Example 20--Citrulline Increased in Gingival Samples in Experiment
Gingivitis
Experimental gingivitis: Another clinical study was carried out to
determine whether citrulline is increased in experimentally induced
gingivitis in healthy human panelists. This was a case-control
study enrolling 60 panelists. The study population included two
groups as follows: Group 1 or high bleeders group, thirty (30)
panelists with at least 20 bleeding sites, where bleeding is a GBI
site score of 1 or 2 at baseline. Group 2 or low bleeders group,
thirty (30) panelists with 2 or less bleeding sites, where bleeding
is a GBI site score of 1 or 2.
The study consisted of two Phases: Health/Rigorous Hygiene Phase
with dental prophylaxis, polishing and rigorous oral hygiene; and
Induced Gingivitis Phase without oral hygiene. At the Screening
visit, panelists underwent an oral soft tissue assessment and had a
gingivitis evaluation (Modified Gingival Index (MGI) and Gingival
Bleeding Index (GBI). At Visit 2 qualifying panelists received an
oral soft tissue exam followed by a gingivitis evaluation and
gingival plaques and gum swabs were collected for the qPCR, protein
and RNA host biomarker analysis. Following that, all panelists
received dental prophylaxis and entered the Health/Rigorous Hygiene
Phase, lasting two weeks. After two weeks of rigorous hygiene,
panelists entered the Induced Gingivitis Phase, lasting for three
weeks. Oral soft tissue exams and gingivitis were re-evaluated and
all samples (gum swabs) were collected at Baseline, WK0 and
WK2.
Gingival sample collection--A gum swab was collected from each side
of the upper arch using the procedures as described in EXAMPLE 15.
Gum swabs were collected close to the gum line from the buccal
sites only (preferably from four adjacent teeth--preferably from
premolar and molar areas). Panelists rinsed for 30 seconds with 15
ml of Listerine rinse to clean the surface of sampling area. After
the Listerine rinse, panelists rinsed for 30 seconds with 20 ml of
water. Following that, selected sites were isolated with a cotton
roll and gently dried with an air syringe and two gum swabs were
taken with collection brushes/swabs from the gingiva region close
to the gumline of the selected teeth. The samples were placed in a
pre-labeled (panelist ID, sample ID, visit, and date) 1.5 ml
micro-centrifuge tube containing 800 ul DPBS (Dulbecco's
phosphate-buffered saline) (Lifetechnologies, Grand Island, N.Y.)
with protease inhibitors, including AEBSF (4-(2-Aminoethyl)
benzenesulfonyl fluoride hydrochloride) 2 mM, aprotinin 0.3 .mu.M,
Bestatin 130 .mu.M, EDTA (Ethylenediaminetetraacetic acid) 1 mM,
E-64 1 .mu.M, and leupeptin 1 .mu.M. The vials were vortexed/mixed
for 30 seconds, immediately frozen on dry ice, stored and
transferred on dry ice to the lab for biomarker analysis. Samples
from three visits were analyzed using the procedures described in
EXAMPLE 17, and shown in FIG. 20. Those three visits were baseline,
Week 0, (right after the Health/Rigorous Hygiene Phase and before
the induced gingivitis phase) and week 2 (at the end of Induced
Gingivitis Phase). Free citrulline levels were low in both the high
and low bleeders groups at the baseline and week 0, but rose
quickly in the induced gingivitis in both groups at week 2.
Example 21--Levels of Proteins Containing Citrulline Decreased in
Experimentally Induced Gingivitis
The same procedures were used as described in EXAMPLE 17. The
samples were the same as described in EXAMPLE 20. Protein bound
citrulline was lower at the baseline than that at week 0 in both
high and low bleeders groups as shown in FIG. 21 in gingival
tissue. It was low in experimental gingivitis in both groups at
week 2.
Example 22--Levels of Proteins Containing Ornithine Increased in
Gingival Samples in Experiment Gingivitis
The same clinical samples from experimental gingivitis (EXAMPLE 20)
were analyzed using the procedures described in EXAMPLE 17. The
bound ornithine was the lowest at week 0 (FIG. 22) in both groups.
Its levels at the baseline were higher than those at week 0. The
bound ornithine reached peaks when gingivitis was induced in both
groups at week 2. Also it is worth noting the total ornithine (Free
and protein bound ornithine) was increased in the induced
gingivitis (FIG. 23) in both groups.
Example 23--Levels of Proteins Containing Arginine Decreased in
Gingival Samples in Experimentally Induced Gingivitis
The same procedures were used as described in EXAMPLE 17. The
samples were the same as described in EXAMPLE 20. The protein bound
arginine was the lowest in induced gingivitis (FIG. 24) in both
groups. Its levels were higher in WK0 than at Baseline in both
groups. The total arginine in the gingival brush samples displayed
the same patterns as the protein bound one (FIG. 25).
Example 24--Citrulline Inhibited LPS Stimulated Production of
Proinflammatory Cytokine in Human THP-1 Cells
Citrulline was purchased from Sigma-Aldrich (St. Louis, Mo.).
THP1-Dual.TM. cells were purchased from Invivogen (San Diego,
Calif.). Cells were cultured following the manufacturer's
instruction, as described in EXAMPLE 11. For treatment, 0.3 mM to 9
mM of citrulline were first added to the culture medium. Then, 300
ng/ml of P. gingivalis LPS 1690 were added 60 minutes later. After
24 hours of treatment, media was collected and analyzed for
cytokine production using 9-plex kit (Meso Scale Diagnostics
Rockville, Md.).
P. gingivalis LPS 1690 stimulated cytokine production, as shown in
FIG. 26. Citrulline inhibited P. gingivalis LPS 1690 effects on
proinflammatory cytokine production in a dose-dependent manner.
Those cytokines include IL-6, TNF-.alpha., IL-12p70, IL-10, IL-2,
IFN-r and IL-1.beta..
Example 25--Binding of BODIPY-TR-Cadaverine to Bacteria and their
Products
Bacteria and their products can activate TLR2 and TLR4 reporter
genes as described in EXAMPLES 5 and 8. Here, experiments were
carried out to determine whether different bacteria and their
products have different IC50 in reducing fluorescent intensity of
BODIPY-TR-cadaverine, hereinafter referred to as BC, in a procedure
as described in EXAMPLE 4. Briefly, high throughput screen utilizes
the fluorescent dye BODIPY-TR-cadaverine
5-(((4-(4,4-difluoro--(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phen-
oxy)acetyl)amino)pentylamine hydrochloride (BC fluorescent dye),
purchased from Life Technologies (Carlsbad, Calif.), as described
previously by Wood, Miller and David (2004) (Comb Chem High
Throughput Screen 2004 May; 7(3):239-49. Anti-endotoxin agents. 1.
Development of a fluorescent probe displacement method optimized
for the rapid identification of lipopolysaccharide-binding
agents.). The experiment was carried out at room temperature. E.
coli LPS (15 .mu.g/ml) was mixed in a well of a 96-well solid black
flat bottom plate (Corning Incorporated, Corning, N.Y.) with SnF2
and cetylpyridinium chloride in 30 .mu.l of 50 mM Tris buffer at pH
7.4 for 10 min, and then 20 .mu.l of 60 .mu.M BC fluorescent dye
was added right before fluorescence measurement at 21.degree. C.,
or room temperature. Fluorescent measurements were performed in a
SpectraMax M3 automated 96 well plate reader (Molecular Device,
Sunnyvale, Calif.). The excitation wavelength was 580 nM and the
fluorescence emission was measured at 620 nM. The half maximal
inhibitory concentration (IC.sub.50) is a measure of the
effectiveness of bacterial products inhibiting BC emitting
fluorescence. It indicates how much of a bacterial material is
needed to inhibit BC fluorescence by half using GraphPad Prism
software (GraphPad Software, La Jolla, Calif.). As shown in FIGS.
27 and 28, each bacterial product decreases the fluorescent
intensity of BC in a dose-dependent manner. Similarly, the whole
bacterial cells and the supernatant of bacterial growth also
reduced the fluorescence of BC in a dose-dependent fashion (FIGS.
29 and 30).
Example 26--Determination of Bacterial Virulence
Growth of bacteria: Two bacteria, Bacterium A and Bacterium B, were
cultured in Tryptic Soy Broth medium (Sigma-Aldrich, St. Louis,
Mo.) at 37.degree. C. with shaking at 200 rpm. The bacteria were
harvested at 24 hours, and suspended in 0.5 ml of
phosphate-buffered saline, labeled "live". Half ml of "Live"
bacteria was transferred to a 1.5 ml microtube, and heated to
80.degree. C. for 30 min. The heat-treated bacteria were labeled
"Heat-Inactivated", or "Dead".
Measurement of TLR responses in THP-1 gene reporter cells
(NFkB-SEAP): The Live and Heat-Inactivated bacteria were applied to
THP-1 cells as described in EXAMPLE 11. As shown in FIG. 31, EC50
of Bacterium A and B on activation of NFkB-SEAP reporter gene in
THP-1 cells was determined. Both Live and Heat-inactivated (Dead)
bacteria stimulated expression of the NFkB-SEAP reporter gene.
Bacterium B had a lower EC50 than Bacterium A in activating
expression of the NFkB-SEAP reporter gene.
Cytokine production and measurement: Human peripheral bleed
mononuclear cells (hPBMC) were obtained from All Cells company (All
Cells, Alameda, Calif.) as Leukapheresed blood. Leukapheresed blood
was mixed with an equal part of DMEM+glutaGRO supplemented with
9.1% fetal bovine serum and 1% penicillin/streptomycin (Thermo
Fisher, Waltham, Mass.). hPBMC were isolated from the 1:1 mixture
of blood and culture medium by collecting the buffy coat of a
centrifuged Histopaque.RTM.-1077 (Sigma-Aldrich, St. Louis, Mo.)
buffer density gradient. The cells (200,000 cells) were cultured in
200 .mu.l of DMEM+glutaGRO supplemented with 9.1% fetal bovine
serum and 1% penicillin/streptomycin, and treated with Live and
Heat-Inactive bacteria (6,250,000 colony-forming units). The medium
was harvested at 24 hours after adding the bacteria, and analyzed
for proinflammatory cytokines in a kit following manufacturer's
instruction (Meso Scale Diagnostics, Rockville, Md.).
As shown in TABLE 9, both live bacterium A and B stimulated
production of cytokines in hPBMC. Bacteriun B was far more potent
than Bacterium A in promoting production of IFN-.gamma., IL-10,
IL-12p70, IL-1.beta., IL-6, IL-8 and TNF-.alpha. in hPBMC.
TABLE-US-00010 Live Live Statistics Cytokines Bacterium A Bacterium
Mean IFN-.gamma. 867.16 12734.36 Mean IL-10 68.35 412.51 Mean
IL-12p70 23.75 253.47 Mean IL-1.beta. 2300.86 6969.31 Mean IL-2
44.24 65.17 Mean IL-6 3431.05 9963.84 Mean IL-8 65742.91 70357.25
Mean TNF-.alpha. 3710.66 13825.49 Std Dev IFN-.gamma. 488.11
8200.13 Std Dev IL-10 33.56 314.23 Std Dev IL-12p70 14.71 283.33
Std Dev IL-1.beta. 1569.72 7691.93 Std Dev IL-2 32.97 36.29 Std Dev
IL-6 2212.62 6552.12 Std Dev IL-8 18689.24 13669.28 Std Dev
TNF-.alpha. 2503.25 8302.26
The dimensions and values disclosed herein are not to be understood
as being strictly limited to the exact numerical values recited.
Instead, unless otherwise specified, each such dimension is
intended to mean both the recited value and a functionally
equivalent range surrounding that value. For example, a dimension
disclosed as "40 mm" is intended to mean "about 40 mm."
Every document cited herein, including any cross referenced or
related patent or application and any patent application or patent
to which this application claims priority or benefit thereof, is
hereby incorporated herein by reference in its entirety unless
expressly excluded or otherwise limited. The citation of any
document is not an admission that it is prior art with respect to
any invention disclosed or claimed herein or that it alone, or in
any combination with any other reference or references, teaches,
suggests or discloses any such invention. Further, to the extent
that any meaning or definition of a term in this document conflicts
with any meaning or definition of the same term in a document
incorporated by reference, the meaning or definition assigned to
that term in this document shall govern.
While particular embodiments of the present invention have been
illustrated and described, it would be obvious to those skilled in
the art that various other changes and modifications can be made
without departing from the spirit and scope of the invention. It is
therefore intended to cover in the appended claims all such changes
and modifications that are within the scope of this invention.
SEQUENCE LISTINGS
1
91786PRTHomo sapiens 1Met Thr Ser Ile Phe His Phe Ala Ile Ile Phe
Met Leu Ile Leu Gln1 5 10 15Ile Arg Ile Gln Leu Ser Glu Glu Ser Glu
Phe Leu Val Asp Arg Ser 20 25 30Lys Asn Gly Leu Ile His Val Pro Lys
Asp Leu Ser Gln Lys Thr Thr 35 40 45Ile Leu Asn Ile Ser Gln Asn Tyr
Ile Ser Glu Leu Trp Thr Ser Asp 50 55 60Ile Leu Ser Leu Ser Lys Leu
Arg Ile Leu Ile Ile Ser His Asn Arg65 70 75 80Ile Gln Tyr Leu Asp
Ile Ser Val Phe Lys Phe Asn Gln Glu Leu Glu 85 90 95Tyr Leu Asp Leu
Ser His Asn Lys Leu Val Lys Ile Ser Cys His Pro 100 105 110Thr Val
Asn Leu Lys His Leu Asp Leu Ser Phe Asn Ala Phe Asp Ala 115 120
125Leu Pro Ile Cys Lys Glu Phe Gly Asn Met Ser Gln Leu Lys Phe Leu
130 135 140Gly Leu Ser Thr Thr His Leu Glu Lys Ser Ser Val Leu Pro
Ile Ala145 150 155 160His Leu Asn Ile Ser Lys Val Leu Leu Val Leu
Gly Glu Thr Tyr Gly 165 170 175Glu Lys Glu Asp Pro Glu Gly Leu Gln
Asp Phe Asn Thr Glu Ser Leu 180 185 190His Ile Val Phe Pro Thr Asn
Lys Glu Phe His Phe Ile Leu Asp Val 195 200 205Ser Val Lys Thr Val
Ala Asn Leu Glu Leu Ser Asn Ile Lys Cys Val 210 215 220Leu Glu Asp
Asn Lys Cys Ser Tyr Phe Leu Ser Ile Leu Ala Lys Leu225 230 235
240Gln Thr Asn Pro Lys Leu Ser Asn Leu Thr Leu Asn Asn Ile Glu Thr
245 250 255Thr Trp Asn Ser Phe Ile Arg Ile Leu Gln Leu Val Trp His
Thr Thr 260 265 270Val Trp Tyr Phe Ser Ile Ser Asn Val Lys Leu Gln
Gly Gln Leu Asp 275 280 285Phe Arg Asp Phe Asp Tyr Ser Gly Thr Ser
Leu Lys Ala Leu Ser Ile 290 295 300His Gln Val Val Ser Asp Val Phe
Gly Phe Pro Gln Ser Tyr Ile Tyr305 310 315 320Glu Ile Phe Ser Asn
Met Asn Ile Lys Asn Phe Thr Val Ser Gly Thr 325 330 335Arg Met Val
His Met Leu Cys Pro Ser Lys Ile Ser Pro Phe Leu His 340 345 350Leu
Asp Phe Ser Asn Asn Leu Leu Thr Asp Thr Val Phe Glu Asn Cys 355 360
365Gly His Leu Thr Glu Leu Glu Thr Leu Ile Leu Gln Met Asn Gln Leu
370 375 380Lys Glu Leu Ser Lys Ile Ala Glu Met Thr Thr Gln Met Lys
Ser Leu385 390 395 400Gln Gln Leu Asp Ile Ser Gln Asn Ser Val Ser
Tyr Asp Glu Lys Lys 405 410 415Gly Asp Cys Ser Trp Thr Lys Ser Leu
Leu Ser Leu Asn Met Ser Ser 420 425 430Asn Ile Leu Thr Asp Thr Ile
Phe Arg Cys Leu Pro Pro Arg Ile Lys 435 440 445Val Leu Asp Leu His
Ser Asn Lys Ile Lys Ser Ile Pro Lys Gln Val 450 455 460Val Lys Leu
Glu Ala Leu Gln Glu Leu Asn Val Ala Phe Asn Ser Leu465 470 475
480Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser Leu Ser Val Leu Ile
485 490 495Ile Asp His Asn Ser Val Ser His Pro Ser Ala Asp Phe Phe
Gln Ser 500 505 510Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp Asn
Pro Phe Gln Cys 515 520 525Thr Cys Glu Leu Gly Glu Phe Val Lys Asn
Ile Asp Gln Val Ser Ser 530 535 540Glu Val Leu Glu Gly Trp Pro Asp
Ser Tyr Lys Cys Asp Tyr Pro Glu545 550 555 560Ser Tyr Arg Gly Thr
Leu Leu Lys Asp Phe His Met Ser Glu Leu Ser 565 570 575Cys Asn Ile
Thr Leu Leu Ile Val Thr Ile Val Ala Thr Met Leu Val 580 585 590Leu
Ala Val Thr Val Thr Ser Leu Cys Ser Tyr Leu Asp Leu Pro Trp 595 600
605Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr Arg Arg Arg Ala Arg
610 615 620Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His
Ala Phe625 630 635 640Ile Ser Tyr Ser Gly His Asp Ser Phe Trp Val
Lys Asn Glu Leu Leu 645 650 655Pro Asn Leu Glu Lys Glu Gly Met Gln
Ile Cys Leu His Glu Arg Asn 660 665 670Phe Val Pro Gly Lys Ser Ile
Val Glu Asn Ile Ile Thr Cys Ile Glu 675 680 685Lys Ser Tyr Lys Ser
Ile Phe Val Leu Ser Pro Asn Phe Val Gln Ser 690 695 700Glu Trp Cys
His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His705 710 715
720Glu Gly Ser Asn Ser Leu Ile Leu Ile Leu Leu Glu Pro Ile Pro Gln
725 730 735Tyr Ser Ile Pro Ser Ser Tyr His Lys Leu Lys Ser Leu Met
Ala Arg 740 745 750Arg Thr Tyr Leu Glu Trp Pro Lys Glu Lys Ser Lys
Arg Gly Leu Phe 755 760 765Trp Ala Asn Leu Arg Ala Ala Ile Asn Ile
Lys Leu Thr Glu Gln Ala 770 775 780Lys Lys7852784PRTHomo sapiens
2Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser1 5
10 15Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp
Arg 20 25 30Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile
Pro Ser 35 40 45Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn
Asn Arg Ile 50 55 60Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val
Asn Leu Gln Ala65 70 75 80Leu Val Leu Thr Ser Asn Gly Ile Asn Thr
Ile Glu Glu Asp Ser Phe 85 90 95Ser Ser Leu Gly Ser Leu Glu His Leu
Asp Leu Ser Tyr Asn Tyr Leu 100 105 110Ser Asn Leu Ser Ser Ser Trp
Phe Lys Pro Leu Ser Ser Leu Thr Phe 115 120 125Leu Asn Leu Leu Gly
Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu 130 135 140Phe Ser His
Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp145 150 155
160Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu
165 170 175Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu
Pro Lys 180 185 190Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile
Leu His Met Lys 195 200 205Gln His Ile Leu Leu Leu Glu Ile Phe Val
Asp Val Thr Ser Ser Val 210 215 220Glu Cys Leu Glu Leu Arg Asp Thr
Asp Leu Asp Thr Phe His Phe Ser225 230 235 240Glu Leu Ser Thr Gly
Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe 245 250 255Arg Asn Val
Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu 260 265 270Leu
Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr 275 280
285Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile
290 295 300Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His
Ile Pro305 310 315 320Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu
Tyr Ser Leu Thr Glu 325 330 335Arg Val Lys Arg Ile Thr Val Glu Asn
Ser Lys Val Phe Leu Val Pro 340 345 350Cys Leu Leu Ser Gln His Leu
Lys Ser Leu Glu Tyr Leu Asp Leu Ser 355 360 365Glu Asn Leu Met Val
Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp 370 375 380Ala Trp Pro
Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala385 390 395
400Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr
405 410 415Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu
Thr Cys 420 425 430Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser
Ser Thr Arg Ile 435 440 445His Ser Val Thr Gly Cys Ile Pro Lys Thr
Leu Glu Ile Leu Asp Val 450 455 460Ser Asn Asn Asn Leu Asn Leu Phe
Ser Leu Asn Leu Pro Gln Leu Lys465 470 475 480Glu Leu Tyr Ile Ser
Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser 485 490 495Leu Leu Pro
Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr 500 505 510Thr
Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu 515 520
525Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe
530 535 540Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp
Pro Ala545 550 555 560Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg
Gly Gln Gln Val Gln 565 570 575Asp Val Arg Leu Ser Val Ser Glu Cys
His Arg Thr Ala Leu Val Ser 580 585 590Gly Met Cys Cys Ala Leu Phe
Leu Leu Ile Leu Leu Thr Gly Val Leu 595 600 605Cys His Arg Phe His
Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp 610 615 620Leu Gln Ala
Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys625 630 635
640Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu
645 650 655Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe
Lys Leu 660 665 670Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp
Ile Ile Asp Asn 675 680 685Ile Ile Asp Ser Ile Glu Lys Ser His Lys
Thr Val Phe Val Leu Ser 690 695 700Glu Asn Phe Val Lys Ser Glu Trp
Cys Lys Tyr Glu Leu Asp Phe Ser705 710 715 720His Phe Arg Leu Phe
Asp Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu 725 730 735Leu Glu Pro
Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu 740 745 750Arg
Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu 755 760
765Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser
770 775 7803904PRTHomo sapiens 3Met Arg Gln Thr Leu Pro Cys Ile Tyr
Phe Trp Gly Gly Leu Leu Pro1 5 10 15Phe Gly Met Leu Cys Ala Ser Ser
Thr Thr Lys Cys Thr Val Ser His 20 25 30Glu Val Ala Asp Cys Ser His
Leu Lys Leu Thr Gln Val Pro Asp Asp 35 40 45Leu Pro Thr Asn Ile Thr
Val Leu Asn Leu Thr His Asn Gln Leu Arg 50 55 60Arg Leu Pro Ala Ala
Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu65 70 75 80Asp Val Gly
Phe Asn Thr Ile Ser Lys Leu Glu Pro Glu Leu Cys Gln 85 90 95Lys Leu
Pro Met Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu Ser 100 105
110Gln Leu Ser Asp Lys Thr Phe Ala Phe Cys Thr Asn Leu Thr Glu Leu
115 120 125His Leu Met Ser Asn Ser Ile Gln Lys Ile Lys Asn Asn Pro
Phe Val 130 135 140Lys Gln Lys Asn Leu Ile Thr Leu Asp Leu Ser His
Asn Gly Leu Ser145 150 155 160Ser Thr Lys Leu Gly Thr Gln Val Gln
Leu Glu Asn Leu Gln Glu Leu 165 170 175Leu Leu Ser Asn Asn Lys Ile
Gln Ala Leu Lys Ser Glu Glu Leu Asp 180 185 190Ile Phe Ala Asn Ser
Ser Leu Lys Lys Leu Glu Leu Ser Ser Asn Gln 195 200 205Ile Lys Glu
Phe Ser Pro Gly Cys Phe His Ala Ile Gly Arg Leu Phe 210 215 220Gly
Leu Phe Leu Asn Asn Val Gln Leu Gly Pro Ser Leu Thr Glu Lys225 230
235 240Leu Cys Leu Glu Leu Ala Asn Thr Ser Ile Arg Asn Leu Ser Leu
Ser 245 250 255Asn Ser Gln Leu Ser Thr Thr Ser Asn Thr Thr Phe Leu
Gly Leu Lys 260 265 270Trp Thr Asn Leu Thr Met Leu Asp Leu Ser Tyr
Asn Asn Leu Asn Val 275 280 285Val Gly Asn Asp Ser Phe Ala Trp Leu
Pro Gln Leu Glu Tyr Phe Phe 290 295 300Leu Glu Tyr Asn Asn Ile Gln
His Leu Phe Ser His Ser Leu His Gly305 310 315 320Leu Phe Asn Val
Arg Tyr Leu Asn Leu Lys Arg Ser Phe Thr Lys Gln 325 330 335Ser Ile
Ser Leu Ala Ser Leu Pro Lys Ile Asp Asp Phe Ser Phe Gln 340 345
350Trp Leu Lys Cys Leu Glu His Leu Asn Met Glu Asp Asn Asp Ile Pro
355 360 365Gly Ile Lys Ser Asn Met Phe Thr Gly Leu Ile Asn Leu Lys
Tyr Leu 370 375 380Ser Leu Ser Asn Ser Phe Thr Ser Leu Arg Thr Leu
Thr Asn Glu Thr385 390 395 400Phe Val Ser Leu Ala His Ser Pro Leu
His Ile Leu Asn Leu Thr Lys 405 410 415Asn Lys Ile Ser Lys Ile Glu
Ser Asp Ala Phe Ser Trp Leu Gly His 420 425 430Leu Glu Val Leu Asp
Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr 435 440 445Gly Gln Glu
Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser 450 455 460Tyr
Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro465 470
475 480Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val
Asp 485 490 495Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr
Ile Leu Asp 500 505 510Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Asp
Asp Met Leu Glu Gly 515 520 525Leu Glu Lys Leu Glu Ile Leu Asp Leu
Gln His Asn Asn Leu Ala Arg 530 535 540Leu Trp Lys His Ala Asn Pro
Gly Gly Pro Ile Tyr Phe Leu Lys Gly545 550 555 560Leu Ser His Leu
His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu 565 570 575Ile Pro
Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp 580 585
590Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn
595 600 605Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile
Thr Ser 610 615 620Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn
Leu Thr Glu Leu625 630 635 640Asp Met Arg Phe Asn Pro Phe Asp Cys
Thr Cys Glu Ser Ile Ala Trp 645 650 655Phe Val Asn Trp Ile Asn Glu
Thr His Thr Asn Ile Pro Glu Leu Ser 660 665 670Ser His Tyr Leu Cys
Asn Thr Pro Pro His Tyr His Gly Phe Pro Val 675 680 685Arg Leu Phe
Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu 690 695 700Phe
Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val705 710
715 720Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn
Val 725 730 735Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg
Gln Thr Glu 740 745 750Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala
Tyr Lys Asp Lys Asp 755 760 765Trp Val Trp Glu His Phe Ser Ser Met
Glu Lys Glu Asp Gln Ser Leu 770 775 780Lys Phe Cys Leu Glu Glu Arg
Asp Phe Glu Ala Gly Val Phe Glu Leu785 790 795 800Glu Ala Ile Val
Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val 805 810 815Ile Thr
His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val 820 825
830His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile
835 840 845Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His
Ala Leu 850 855 860Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile
Leu Asn Trp Pro865 870 875 880Val Gln Lys Glu Arg Ile Gly Ala Phe
Arg His Lys Leu Gln Val Ala 885 890 895Leu Gly Ser Lys Asn
Ser Val His 9004798PRTHomo sapiens 4Met Glu Leu Asn Phe Tyr Lys Ile
Pro Asp Asn Leu Pro Phe Ser Thr1 5 10 15Lys Asn Leu Asp Leu Ser Phe
Asn Pro Leu Arg His Leu Gly Ser Tyr 20 25 30Ser Phe Phe Ser Phe Pro
Glu Leu Gln Val Leu Asp Leu Ser Arg Cys 35 40 45Glu Ile Gln Thr Ile
Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu 50 55 60Ser Thr Leu Ile
Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly65 70 75 80Ala Phe
Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr 85 90 95Asn
Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu 100 105
110Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro
115 120 125Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu
Ser Ser 130 135 140Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg
Val Leu His Gln145 150 155 160Met Pro Leu Leu Asn Leu Ser Leu Asp
Leu Ser Leu Asn Pro Met Asn 165 170 175Phe Ile Gln Pro Gly Ala Phe
Lys Glu Ile Arg Leu His Lys Leu Thr 180 185 190Leu Arg Asn Asn Phe
Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln 195 200 205Gly Leu Ala
Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg 210 215 220Asn
Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu225 230
235 240Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr
Tyr 245 250 255Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn
Val Ser Ser 260 265 270Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val
Lys Asp Phe Ser Tyr 275 280 285Asn Phe Gly Trp Gln His Leu Glu Leu
Val Asn Cys Lys Phe Gly Gln 290 295 300Phe Pro Thr Leu Lys Leu Lys
Ser Leu Lys Arg Leu Thr Phe Thr Ser305 310 315 320Asn Lys Gly Gly
Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu 325 330 335Phe Leu
Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser 340 345
350Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe
355 360 365Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu
Gln Leu 370 375 380Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln
Met Ser Glu Phe385 390 395 400Ser Val Phe Leu Ser Leu Arg Asn Leu
Ile Tyr Leu Asp Ile Ser His 405 410 415Thr His Thr Arg Val Ala Phe
Asn Gly Ile Phe Asn Gly Leu Ser Ser 420 425 430Leu Glu Val Leu Lys
Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu 435 440 445Pro Asp Ile
Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser 450 455 460Gln
Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser465 470
475 480Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu
Asp 485 490 495Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu
Asp Tyr Ser 500 505 510Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu
Leu Gln His Phe Pro 515 520 525Ser Ser Leu Ala Phe Leu Asn Leu Thr
Gln Asn Asp Phe Ala Cys Thr 530 535 540Cys Glu His Gln Ser Phe Leu
Gln Trp Ile Lys Asp Gln Arg Gln Leu545 550 555 560Leu Val Glu Val
Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln 565 570 575Gly Met
Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr 580 585
590Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala
595 600 605Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala
Gly Cys 610 615 620Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala
Phe Val Ile Tyr625 630 635 640Ser Ser Gln Asp Glu Asp Trp Val Arg
Asn Glu Leu Val Lys Asn Leu 645 650 655Glu Glu Gly Val Pro Pro Phe
Gln Leu Cys Leu His Tyr Arg Asp Phe 660 665 670Ile Pro Gly Val Ala
Ile Ala Ala Asn Ile Ile His Glu Gly Phe His 675 680 685Lys Ser Arg
Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser 690 695 700Arg
Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu705 710
715 720Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu
Lys 725 730 735Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu
Ser Arg Asn 740 745 750Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly
Arg His Ile Phe Trp 755 760 765Arg Arg Leu Arg Lys Ala Leu Leu Asp
Gly Lys Ser Trp Asn Pro Glu 770 775 780Gly Thr Val Gly Thr Gly Cys
Asn Trp Gln Glu Ala Thr Ser785 790 7955858PRTHomo sapiens 5Met Gly
Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly1 5 10 15Pro
Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe 20 25
30Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr
35 40 45Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala
Ser 50 55 60Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly
Ser Gln65 70 75 80Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg
Asn Leu Pro Asn 85 90 95Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile
Tyr Phe Leu His Pro 100 105 110Asp Ala Phe Gln Gly Leu Phe His Leu
Phe Glu Leu Arg Leu Tyr Phe 115 120 125Cys Gly Leu Ser Asp Ala Val
Leu Lys Asp Gly Tyr Phe Arg Asn Leu 130 135 140Lys Ala Leu Thr Arg
Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu145 150 155 160Tyr Leu
His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp 165 170
175Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro
180 185 190Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn
Ser Leu 195 200 205Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met
Asn Pro Phe Arg 210 215 220Asn Met Val Leu Glu Ile Leu Asp Val Ser
Gly Asn Gly Trp Thr Val225 230 235 240Asp Ile Thr Gly Asn Phe Ser
Asn Ala Ile Ser Lys Ser Gln Ala Phe 245 250 255Ser Leu Ile Leu Ala
His His Ile Met Gly Ala Gly Phe Gly Phe His 260 265 270Asn Ile Lys
Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser 275 280 285Ser
Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn 290 295
300Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu
Ala305 310 315 320Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe
Tyr Gly Leu Asp 325 330 335Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn
Leu Leu Gly Glu Leu Tyr 340 345 350Ser Ser Asn Phe Tyr Gly Leu Pro
Lys Val Ala Tyr Ile Asp Leu Gln 355 360 365Lys Asn His Ile Ala Ile
Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu 370 375 380Lys Leu Gln Thr
Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His385 390 395 400Phe
Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val 405 410
415Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu
420 425 430Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg
Val Pro 435 440 445His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe
Ser Ser Cys Ser 450 455 460Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser
Leu Glu Gln Leu Phe Leu465 470 475 480Gly Glu Asn Met Leu Gln Leu
Ala Trp Glu Thr Glu Leu Cys Trp Asp 485 490 495Val Phe Glu Gly Leu
Ser His Leu Gln Val Leu Tyr Leu Asn His Asn 500 505 510Tyr Leu Asn
Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu 515 520 525Arg
Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn 530 535
540Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln
Leu545 550 555 560Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser
Val Leu Asp Ile 565 570 575Thr His Asn Lys Phe Ile Cys Glu Cys Glu
Leu Ser Thr Phe Ile Asn 580 585 590Trp Leu Asn His Thr Asn Val Thr
Ile Ala Gly Pro Pro Ala Asp Ile 595 600 605Tyr Cys Val Tyr Pro Asp
Ser Phe Ser Gly Val Ser Leu Phe Ser Leu 610 615 620Ser Thr Glu Gly
Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe625 630 635 640Ser
Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr 645 650
655Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys
660 665 670Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr
Glu Pro 675 680 685Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser
Ser Lys Asp Phe 690 695 700Thr Trp Val Gln Asn Ala Leu Leu Lys His
Leu Asp Thr Gln Tyr Ser705 710 715 720Asp Gln Asn Arg Phe Asn Leu
Cys Phe Glu Glu Arg Asp Phe Val Pro 725 730 735Gly Glu Asn Arg Ile
Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg 740 745 750Lys Ile Val
Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys 755 760 765Leu
Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn 770 775
780Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln
Leu785 790 795 800Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys
Gln Gln Tyr Leu 805 810 815Arg Trp Pro Glu Asp Leu Gln Asp Val Gly
Trp Phe Leu His Lys Leu 820 825 830Ser Gln Gln Ile Leu Lys Lys Glu
Lys Glu Lys Lys Lys Asp Asn Asn 835 840 845Ile Pro Leu Gln Thr Val
Ala Thr Ile Ser 850 8556796PRTHomo sapiens 6Met Thr Lys Asp Lys Glu
Pro Ile Val Lys Ser Phe His Phe Val Cys1 5 10 15Leu Met Ile Ile Ile
Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn 20 25 30Glu Phe Ala Val
Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys 35 40 45Asp Leu Pro
Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile 50 55 60Ala Glu
Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val65 70 75
80Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe
85 90 95Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln
Leu 100 105 110Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His
Leu Asp Leu 115 120 125Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys
Lys Glu Phe Gly Asn 130 135 140Leu Ser Gln Leu Asn Phe Leu Gly Leu
Ser Ala Met Lys Leu Gln Lys145 150 155 160Leu Asp Leu Leu Pro Ile
Ala His Leu His Leu Ser Tyr Ile Leu Leu 165 170 175Asp Leu Arg Asn
Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln 180 185 190Ile Leu
Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu 195 200
205Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln
210 215 220Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe
Ile Lys225 230 235 240Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu
Leu Asn Phe Thr Leu 245 250 255Asn His Ile Glu Thr Thr Trp Lys Cys
Leu Val Arg Val Phe Gln Phe 260 265 270Leu Trp Pro Lys Pro Val Glu
Tyr Leu Asn Ile Tyr Asn Leu Thr Ile 275 280 285Ile Glu Ser Ile Arg
Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu 290 295 300Lys Ala Leu
Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser305 310 315
320Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu
325 330 335Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His
Ala Pro 340 345 350Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val
Phe Thr Asp Ser 355 360 365Ile Phe Glu Lys Cys Ser Thr Leu Val Lys
Leu Glu Thr Leu Ile Leu 370 375 380Gln Lys Asn Gly Leu Lys Asp Leu
Phe Lys Val Gly Leu Met Thr Lys385 390 395 400Asp Met Pro Ser Leu
Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu 405 410 415Ser Gly Arg
His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val 420 425 430Leu
Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu 435 440
445Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser
450 455 460Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu
Asn Val465 470 475 480Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys
Gly Ser Phe Ser Ser 485 490 495Leu Ser Val Leu Ile Ile Asp His Asn
Ser Val Ser His Pro Ser Ala 500 505 510Asp Phe Phe Gln Ser Cys Gln
Lys Met Arg Ser Ile Lys Ala Gly Asp 515 520 525Asn Pro Phe Gln Cys
Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile 530 535 540Asp Gln Val
Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys545 550 555
560Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His
565 570 575Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr
Ile Gly 580 585 590Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser
Leu Cys Ile Tyr 595 600 605Leu Asp Leu Pro Trp Tyr Leu Arg Met Val
Cys Gln Trp Thr Gln Thr 610 615 620Arg Arg Arg Ala Arg Asn Ile Pro
Leu Glu Glu Leu Gln Arg Asn Leu625 630 635 640Gln Phe His Ala Phe
Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val 645 650 655Lys Ser Glu
Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys 660 665 670Leu
His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile 675 680
685Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro
690 695 700Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe
Ala His705 710 715 720His Asn Leu Phe His Glu Gly Ser Asn Asn Leu
Ile Leu Ile Leu Leu 725 730 735Glu Pro Ile Pro Gln Asn Ser Ile Pro
Asn Lys Tyr His Lys Leu Lys 740 745 750Ala Leu Met Thr Gln Arg Thr
Tyr Leu Gln Trp Pro Lys Glu Lys Ser 755 760 765Lys Arg Gly Leu Phe
Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys 770 775 780Leu Thr Leu
Val Thr Glu Asn Asn Asp Val Lys Ser785 790 79571049PRTHomo sapiens
7Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu
Phe1
5 10 15Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro
Lys 20 25 30Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His
Val Ile 35 40 45Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly
Gly Ile Pro 50 55 60Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His
Ile Pro Asp Ile65 70 75 80Ser Pro Ala Ser Phe His Arg Leu Asp His
Leu Val Glu Ile Asp Phe 85 90 95Arg Cys Asn Cys Val Pro Ile Pro Leu
Gly Ser Lys Asn Asn Met Cys 100 105 110Ile Lys Arg Leu Gln Ile Lys
Pro Arg Ser Phe Ser Gly Leu Thr Tyr 115 120 125Leu Lys Ser Leu Tyr
Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln 130 135 140Gly Leu Pro
Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile145 150 155
160Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile
165 170 175Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr
Val Ser 180 185 190Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr
Lys Leu Lys Val 195 200 205Leu Ser Leu Lys Asp Asn Asn Val Thr Ala
Val Pro Thr Val Leu Pro 210 215 220Ser Thr Leu Thr Glu Leu Tyr Leu
Tyr Asn Asn Met Ile Ala Lys Ile225 230 235 240Gln Glu Asp Asp Phe
Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu 245 250 255Ser Gly Asn
Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro 260 265 270Cys
Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala 275 280
285Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290 295 300Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu
Leu Asp305 310 315 320Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly
Asp Ala Lys Phe Leu 325 330 335His Phe Leu Pro Ser Leu Ile Gln Leu
Asp Leu Ser Phe Asn Phe Glu 340 345 350Leu Gln Val Tyr Arg Ala Ser
Met Asn Leu Ser Gln Ala Phe Ser Ser 355 360 365Leu Lys Ser Leu Lys
Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu 370 375 380Leu Lys Ser
Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu385 390 395
400Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met
405 410 415Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val
Asn Lys 420 425 430Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe
Cys Ser Asn Ala 435 440 445Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln
Val Leu Glu Gln Leu His 450 455 460Tyr Phe Arg Tyr Asp Lys Tyr Ala
Arg Ser Cys Arg Phe Lys Asn Lys465 470 475 480Glu Ala Ser Phe Met
Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln 485 490 495Thr Leu Asp
Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp 500 505 510Phe
Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu 515 520
525Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu
530 535 540Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His
Ser Thr545 550 555 560Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu
Asp Ile Ser Ser Asn 565 570 575Ser His Tyr Phe Gln Ser Glu Gly Ile
Thr His Met Leu Asn Phe Thr 580 585 590Lys Asn Leu Lys Val Leu Gln
Lys Leu Met Met Asn Asp Asn Asp Ile 595 600 605Ser Ser Ser Thr Ser
Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu 610 615 620Glu Phe Arg
Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn625 630 635
640Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp
645 650 655Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe
Asp Gly 660 665 670Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys
Asn Gly Leu Lys 675 680 685Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu
Lys Asn Leu Glu Thr Leu 690 695 700Asp Leu Ser His Asn Gln Leu Thr
Thr Val Pro Glu Arg Leu Ser Asn705 710 715 720Cys Ser Arg Ser Leu
Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg 725 730 735Ser Leu Thr
Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu 740 745 750Asp
Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro 755 760
765Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg
770 775 780Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val
Asn His785 790 795 800Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp
Val Thr Cys Val Gly 805 810 815Pro Gly Ala His Lys Gly Gln Ser Val
Ile Ser Leu Asp Leu Tyr Thr 820 825 830Cys Glu Leu Asp Leu Thr Asn
Leu Ile Leu Phe Ser Leu Ser Ile Ser 835 840 845Val Ser Leu Phe Leu
Met Val Met Met Thr Ala Ser His Leu Tyr Phe 850 855 860Trp Asp Val
Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly865 870 875
880Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val
885 890 895Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala
Glu Leu 900 905 910Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe
Asn Leu Cys Leu 915 920 925Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro
Val Leu Glu Asn Leu Ser 930 935 940Gln Ser Ile Gln Leu Ser Lys Lys
Thr Val Phe Val Met Thr Asp Lys945 950 955 960Tyr Ala Lys Thr Glu
Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln 965 970 975Arg Leu Met
Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu 980 985 990Lys
Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys 995
1000 1005Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His
Pro 1010 1015 1020Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr
Asp Asn His 1025 1030 1035Val Ala Tyr Ser Gln Val Phe Lys Glu Thr
Val 1040 104581041PRTHomo sapiens 8Met Glu Asn Met Phe Leu Gln Ser
Ser Met Leu Thr Cys Ile Phe Leu1 5 10 15Leu Ile Ser Gly Ser Cys Glu
Leu Cys Ala Glu Glu Asn Phe Ser Arg 20 25 30Ser Tyr Pro Cys Asp Glu
Lys Lys Gln Asn Asp Ser Val Ile Ala Glu 35 40 45Cys Ser Asn Arg Arg
Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr 50 55 60Val Thr Glu Leu
Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn65 70 75 80Glu Ser
Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His 85 90 95Asn
Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn 100 105
110Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg
115 120 125Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser
Gly Leu 130 135 140Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn
Asn Ile Tyr Asn145 150 155 160Ile Thr Lys Glu Gly Ile Ser Arg Leu
Ile Asn Leu Lys Asn Leu Tyr 165 170 175Leu Ala Trp Asn Cys Tyr Phe
Asn Lys Val Cys Glu Lys Thr Asn Ile 180 185 190Glu Asp Gly Val Phe
Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu 195 200 205Ser Phe Asn
Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu 210 215 220Arg
Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu225 230
235 240Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly
Asn 245 250 255Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro
Cys Asp Gly 260 265 270Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe
Gln Asn Leu Thr Gln 275 280 285Leu Arg Tyr Leu Asn Leu Ser Ser Thr
Ser Leu Arg Lys Ile Asn Ala 290 295 300Ala Trp Phe Lys Asn Met Pro
His Leu Lys Val Leu Asp Leu Glu Phe305 310 315 320Asn Tyr Leu Val
Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu 325 330 335Pro Arg
Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser 340 345
350Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser
355 360 365Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu
Arg Glu 370 375 380Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu
Ser Thr Ile Asn385 390 395 400Leu Gly Ile Asn Phe Ile Lys Gln Ile
Asp Phe Lys Leu Phe Gln Asn 405 410 415Phe Ser Asn Leu Glu Ile Ile
Tyr Leu Ser Glu Asn Arg Ile Ser Pro 420 425 430Leu Val Lys Asp Thr
Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln 435 440 445Arg His Ile
Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His 450 455 460Ser
Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala465 470
475 480Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe
Ile 485 490 495Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys
Leu Asn Leu 500 505 510Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly
Thr Glu Phe Ser Ala 515 520 525Ile Pro His Val Lys Tyr Leu Asp Leu
Thr Asn Asn Arg Leu Asp Phe 530 535 540Asp Asn Ala Ser Ala Leu Thr
Glu Leu Ser Asp Leu Glu Val Leu Asp545 550 555 560Leu Ser Tyr Asn
Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His 565 570 575Leu Glu
Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser 580 585
590His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys
595 600 605Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile
Leu Trp 610 615 620Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys
Gly Leu Lys Asn625 630 635 640Leu Thr Arg Leu Asp Leu Ser Leu Asn
Arg Leu Lys His Ile Pro Asn 645 650 655Glu Ala Phe Leu Asn Leu Pro
Ala Ser Leu Thr Glu Leu His Ile Asn 660 665 670Asp Asn Met Leu Lys
Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro 675 680 685Arg Leu Glu
Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr 690 695 700Asp
Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser705 710
715 720His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val
Ser 725 730 735Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys
Thr Ile Asn 740 745 750Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys
Leu Ser Met Leu Glu 755 760 765Leu His Gly Asn Pro Phe Glu Cys Thr
Cys Asp Ile Gly Asp Phe Arg 770 775 780Arg Trp Met Asp Glu His Leu
Asn Val Lys Ile Pro Arg Leu Val Asp785 790 795 800Val Ile Cys Ala
Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser 805 810 815Leu Glu
Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe 820 825
830Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala
835 840 845His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val
Cys Leu 850 855 860Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser
Gln Thr Phe Tyr865 870 875 880Asp Ala Tyr Ile Ser Tyr Asp Thr Lys
Asp Ala Ser Val Thr Asp Trp 885 890 895Val Ile Asn Glu Leu Arg Tyr
His Leu Glu Glu Ser Arg Asp Lys Asn 900 905 910Val Leu Leu Cys Leu
Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile 915 920 925Ile Asp Asn
Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe 930 935 940Val
Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe945 950
955 960Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile
Ile 965 970 975Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr
Leu Arg Leu 980 985 990Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln
Trp Pro Asp Asn Pro 995 1000 1005Lys Ala Glu Gly Leu Phe Trp Gln
Thr Leu Arg Asn Val Val Leu 1010 1015 1020Thr Glu Asn Asp Ser Arg
Tyr Asn Asn Met Tyr Val Asp Ser Ile 1025 1030 1035Lys Gln Tyr
104091032PRTHomo sapiens 9Met Gly Phe Cys Arg Ser Ala Leu His Pro
Leu Ser Leu Leu Val Gln1 5 10 15Ala Ile Met Leu Ala Met Thr Leu Ala
Leu Gly Thr Leu Pro Ala Phe 20 25 30Leu Pro Cys Glu Leu Gln Pro His
Gly Leu Val Asn Cys Asn Trp Leu 35 40 45Phe Leu Lys Ser Val Pro His
Phe Ser Met Ala Ala Pro Arg Gly Asn 50 55 60Val Thr Ser Leu Ser Leu
Ser Ser Asn Arg Ile His His Leu His Asp65 70 75 80Ser Asp Phe Ala
His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp 85 90 95Asn Cys Pro
Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110Thr
Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120
125Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
130 135 140Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu
Asp Ser145 150 155 160Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe
Leu Phe Met Asp Gly 165 170 175Asn Cys Tyr Tyr Lys Asn Pro Cys Arg
Gln Ala Leu Glu Val Ala Pro 180 185 190Gly Ala Leu Leu Gly Leu Gly
Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205Asn Asn Leu Thr Val
Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr 210 215 220Leu Leu Leu
Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu225 230 235
240Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg
His Phe 260 265 270Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser
Arg Leu Glu Gly 275 280 285Leu Val Leu Lys Asp Ser Ser Leu Ser Trp
Leu Asn Ala Ser Trp Phe 290 295 300Arg Gly Leu Gly Asn Leu Arg Val
Leu Asp Leu Ser Glu Asn Phe Leu305 310 315 320Tyr Lys Cys Ile Thr
Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu 325 330 335Arg Lys Leu
Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala 340 345 350His
Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu 355 360
365Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
370 375 380Arg Pro Leu Ala Arg Leu Pro Met Leu Gln
Thr Leu Arg Leu Gln Met385 390 395 400Asn Phe Ile Asn Gln Ala Gln
Leu Gly Ile Phe Arg Ala Phe Pro Gly 405 410 415Leu Arg Tyr Val Asp
Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu 420 425 430Leu Thr Ala
Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu 435 440 445Gln
Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu 450 455
460Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu
Ser465 470 475 480Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe
Ala Gln Leu Ser 485 490 495His Leu Gln Cys Leu Arg Leu Ser His Asn
Cys Ile Ser Gln Ala Val 500 505 510Asn Gly Ser Gln Phe Leu Pro Leu
Thr Gly Leu Gln Val Leu Asp Leu 515 520 525Ser His Asn Lys Leu Asp
Leu Tyr His Glu His Ser Phe Thr Glu Leu 530 535 540Pro Arg Leu Glu
Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly545 550 555 560Met
Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr 565 570
575Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
580 585 590Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser
Gly Asn 595 600 605Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr
Leu His Phe Phe 610 615 620Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp
Leu Ser Gln Asn Arg Leu625 630 635 640His Thr Leu Leu Pro Gln Thr
Leu Arg Asn Leu Pro Lys Ser Leu Gln 645 650 655Val Leu Arg Leu Arg
Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser 660 665 670Leu His Phe
Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln 675 680 685Leu
Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg 690 695
700Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly
Phe705 710 715 720Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu
Ser Ala Asn Ala 725 730 735Leu Lys Thr Val Asp His Ser Trp Phe Gly
Pro Leu Ala Ser Ala Leu 740 745 750Gln Ile Leu Asp Val Ser Ala Asn
Pro Leu His Cys Ala Cys Gly Ala 755 760 765Ala Phe Met Asp Phe Leu
Leu Glu Val Gln Ala Ala Val Pro Gly Leu 770 775 780Pro Ser Arg Val
Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser785 790 795 800Ile
Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 805 810
815Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val
820 825 830Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys
Phe His 835 840 845Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln
Ser Gly Arg Asp 850 855 860Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val
Val Phe Asp Lys Thr Gln865 870 875 880Ser Ala Val Ala Asp Trp Val
Tyr Asn Glu Leu Arg Gly Gln Leu Glu 885 890 895Glu Cys Arg Gly Arg
Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp 900 905 910Trp Leu Pro
Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr 915 920 925Gly
Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser 930 935
940Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu
Glu945 950 955 960Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser
Pro Asp Gly Arg 965 970 975Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg
Leu Cys Arg Gln Ser Val 980 985 990Leu Leu Trp Pro His Gln Pro Ser
Gly Gln Arg Ser Phe Trp Ala Gln 995 1000 1005Leu Gly Met Ala Leu
Thr Arg Asp Asn His His Phe Tyr Asn Arg 1010 1015 1020Asn Phe Cys
Gln Gly Pro Thr Ala Glu 1025 1030
* * * * *
References